FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Pfaller

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Disorders

Physiology

Co-author Network

Publications

TOP 3
Daniel J Diekema; Michael A Pfaller
Rapid detection of antibiotic-resistant organism carriage for infection prevention.
Michael A Pfaller; Leah N Woosley; Ronald N Jones; Shawn A Messer; Mariana Castanheira
Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.
Michael A Pfaller; V Chaturvedi; Daniel J Diekema; Mahmoud A Ghannoum; N M Holliday; Scott B Killian; Cindy C Knapp; Shawn A Messer; A Miskou; R Ramani
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Pfaller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Daniel J Diekema; Michael A Pfaller
Rapid detection of antibiotic-resistant organism carriage for infection prevention.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;56(11):1614-20.
2012: Michael A Pfaller; Leah N Woosley; Ronald N Jones; Shawn A Messer; Mariana Castanheira
Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.
Mycopathologia 2012;174(4):259-71.
2012: Michael A Pfaller; V Chaturvedi; Daniel J Diekema; Mahmoud A Ghannoum; N M Holliday; Scott B Killian; Cindy C Knapp; Shawn A Messer; A Miskou; R Ramani
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Diagnostic microbiology and infectious disease 2012;73(4):365-8.
2011: Michael A Pfaller; Shawn A Messer; Mariana Castanheira; Daniel J Diekema; Ronald N Jones
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.
Journal of clinical microbiology 2011;49(11):3800-4.
2011: Michael A Pfaller; Frederick Duncanson; Ronald N Jones; Shawn A Messer; Gary J Moet; Mariana Castanheira
In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Antimicrobial agents and chemotherapy 2011;55(11):5155-8.
2011: Shawn R Lockhart; Michael A Pfaller; Daniel J Diekema; Kizee A Etienne; Joao Frade; S Arunmozhi Balajee
Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene.
Antimicrobial agents and chemotherapy 2011;55(9):4465-8.
2011: Michael A Pfaller; Barbara D Alexander; David Andes; Maiken C Arendrup; Steven D Brown; Vishnu Chaturvedi; Daniel J Diekema; Ana Espinel-Ingroff; Cynthia L Fowler; Mahmoud A Ghannoum; Elizabeth M Johnson; Cynthia C Knapp; Mary R Motyl; Luis Ostrosky-Zeichner; THOMAS WALSH
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
Diagnostic microbiology and infectious disease 2011;70(3):330-43.
2011: Michael A Pfaller; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
International journal of antimicrobial agents 2011;38(1):65-9.
2011: Michael A Pfaller; D Andes; M C Arendrup; S D Brown; Daniel J Diekema; S R Lockhart; M Motyl; D S Perlin
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2011;14(3):164-76.
2011: Michael A Pfaller; L B Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.
Journal of clinical microbiology 2011;49(4):1274-9.
2011: Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; THOMAS WALSH; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Naureen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
Antimicrobial agents and chemotherapy 2011;55(4):1543-8.
2011: Michael A Pfaller; Ana Espinel-Ingroff; Linda Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
Journal of clinical microbiology 2011;49(3):845-50.
2011: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn Messer; Shailesh Tendolkar; Daniel Diekema
Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.
Journal of clinical microbiology 2011;49(3):1110-2.
2011: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
Journal of clinical microbiology 2011;49(2):630-7.
2011: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn Messer; Shailesh Tendolkar; Daniel Diekema
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Journal of clinical microbiology 2011;49(2):624-9.
2011: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn Messer; Shailesh Tendolkar; Daniel Diekema
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.
Journal of clinical microbiology 2011;49(2):586-90.
2010: Michael A Pfaller; Richard J Hollis; B P Goldstein; Shawn Messer; Daniel Diekema; T Henkel
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.
Journal of clinical microbiology 2010;48(7):2613-4.
2010: David Andes; D J Diekema; Michael A Pfaller; J Bohrmuller; Karen Marchillo; A Lepak
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Antimicrobial agents and chemotherapy 2010;54(6):2497-506.
2010: Michael A Pfaller; Daniel J Diekema; DL Gibbs; VA Newell; Richard Barton; Hu Bijie; Jacques Bille; Shan-Chwen Chang; Maria da Luz Martins; Adriano Duse; Danuta Dzierzanowska; David Ellis; Jorge Finquelievich; Ian Gould; Deniz Gur; Anwar Hoosen; Kyungwon Lee; Nada Mallatova; Michele Mallie; N G Kee Peng; George Petrikos; Axel Santiago; Jan Trupl; Ann Marie VanDen Abeele; Jeannette Wadula; Mussaret Zaidi
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Diagnostic microbiology and infectious disease 2010;67(2):162-71.
2010: Dionissios Neofytos; J A Fishman; David Horn; E Anaissie; C-H Chang; Ali S Olyaei; Michael A Pfaller; W J Steinbach; K M Webster; Kieren Marr
Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients.
Transplant infectious disease : an official journal of the Transplantation Society 2010;12(3):220-9.
2010: Michael A Pfaller; M Castanheira; Daniel J Diekema; Shawn A Messer; G J Moet; Ronald Jones
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
Journal of clinical microbiology 2010;48(5):1592-9.
2010: Michael A Pfaller; Linda Boyken; Richard J Hollis; Jennifer Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.
Diagnostic microbiology and infectious disease 2010;67(1):56-60.
2010: Michael A Pfaller; Daniel J Diekema; DL Gibbs; VA Newell; D Ellis; V Tullio; A Rodloff; W Fu; T A Ling
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
Journal of clinical microbiology 2010;48(4):1366-77.
2010: Michael A Pfaller; Mariana Castanheira; Helio S Sader; Ronald N Jones
Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.
International journal of antimicrobial agents 2010;35(3):282-7.
2010: Michael A Pfaller; Daniel J Diekema
Epidemiology of invasive mycoses in North America.
Critical reviews in microbiology 2010;36(1):1-53.
2010: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Ronald Jones; J Turnidge; Daniel J Diekema
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
Journal of clinical microbiology 2010;48(1):52-6.
2009: Kizee A Etienne; Lalitha Gade; Shawn R Lockhart; Daniel J Diekema; Shawn A Messer; Michael A Pfaller; S Arunmozhi Balajee
Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay.
Journal of clinical microbiology 2009;47(12):4171-2.
2009: Michael A Pfaller; Shawn A Messer; N Georgopapadakou; L A Martell; J M Besterman; Daniel J Diekema
Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
Journal of clinical microbiology 2009;47(12):3797-804.
2009: Emilia Siikala; Malcolm Richardson; Michael A Pfaller; Daniel J Diekema; Shawn A Messer; Jaakko Perheentupa; Harri Saxén; Riina Rautemaa
Candida albicans isolates from APECED patients show decreased susceptibility to miconazole.
International journal of antimicrobial agents 2009;34(6):607-9.
2009: Daniel J Diekema; Shawn A Messer; L B Boyken; Richard J Hollis; J Kroeger; Shailesh Tendolkar; Michael A Pfaller
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.
Journal of clinical microbiology 2009;47(10):3170-7.
2009: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.
Journal of clinical microbiology 2009;47(10):3323-5.
2009: Michael A Pfaller; Daniel J Diekema; Mahmoud A Ghannoum; John H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; Ana Espinel-Ingroff; C L Fowler; E M Johnson; Cindy C Knapp; M R Motyl; L Ostrosky-Zeichner; D J Sheehan; THOMAS WALSH
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
Journal of clinical microbiology 2009;47(10):3142-6.
2009: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Linda Boyken; Shailesh Tendolkar; J Kroeger; Daniel J Diekema
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.
Journal of clinical microbiology 2009;47(10):3185-90.
2009: Michael A Pfaller; Linda Boyken; Richard J Hollis; Jennifer Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
Diagnostic microbiology and infectious disease 2009;65(1):27-34.
2009: David L Horn; Dionissios Neofytos; Elias J Anaissie; Jay A Fishman; William J Steinbach; Ali S Olyaei; Kieren Marr; Michael A Pfaller; Chi-Hsing Chang; Karen M Webster
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(12):1695-703.
2009: Michael J Klevay; David L Horn; Dionissios Neofytos; Michael A Pfaller; Daniel J Diekema
Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Diagnostic microbiology and infectious disease 2009;64(2):152-7.
2009: Shawn R Lockhart; Shawn A Messer; Michael Gherna; Justin A Bishop; William G Merz; Michael A Pfaller; Daniel J Diekema
Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature.
Journal of clinical microbiology 2009;47(4):1216-7.
2009: Daniel J Diekema; Shawn A Messer; Richard J Hollis; Linda Boyken; Shailesh Tendolkar; Jennifer Kroeger; Ronald N Jones; Michael A Pfaller
A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Diagnostic microbiology and infectious disease 2009;63(2):233-6.
2009: Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates.
Journal of clinical microbiology 2009;47(1):242-4.
2009: Michael A Pfaller; Daniel J Diekema; DL Gibbs; VA Newell; H Bijie; D Dzierzanowska; N N Klimko; V Letscher-Bru; M Lisalova; K Muehlethaler; C Rennison; M Zaidi
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Journal of clinical microbiology 2009;47(1):117-23.
2008: Luis Ostrosky-Zeichner; John H Rex; Michael A Pfaller; Daniel J Diekema; Barbara D Alexander; David Andes; Steven D Brown; Vishnu Chaturvedi; Mahmoud A Ghannoum; Cindy C Knapp; Daniel J Sheehan; THOMAS WALSH
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.
Antimicrobial agents and chemotherapy 2008;52(11):4175-7.
2008: Michael A Pfaller; L B Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.
Journal of clinical microbiology 2008;46(11):3585-90.
2008: David Andes; D J Diekema; Michael A Pfaller; Karen Marchillo; J Bohrmueller
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Antimicrobial agents and chemotherapy 2008;52(10):3497-503.
2008: Riina Rautemaa; Malcolm Richardson; Michael A Pfaller; Jaakko Perheentupa; Harri Saxén
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Diagnostic microbiology and infectious disease 2008;62(2):182-5.
2008: Lauren Wrobel; Julia K Whittington; Claude Pujol; Soon-Hwan Oh; Marilyn O Ruiz; Michael A Pfaller; Daniel J Diekema; David Soll; Lois L Hoyer
Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois.
Eukaryotic cell 2008;7(9):1475-86.
2008: Michael A Pfaller; Daniel J Diekema; L Ostrosky-Zeichner; John H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; Mahmoud A Ghannoum; Cindy C Knapp; D J Sheehan; THOMAS WALSH
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Journal of clinical microbiology 2008;46(8):2620-9.
2008: Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.
Journal of clinical microbiology 2008;46(8):2659-64.
2008: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.
Journal of clinical microbiology 2008;46(8):2568-72.
2008: Michael A Pfaller; V Chaturvedi; Daniel J Diekema; Mahmoud A Ghannoum; N M Holliday; Scott B Killian; Cindy C Knapp; Shawn A Messer; A Miskov; R Ramani
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
Journal of clinical microbiology 2008;46(7):2155-9.
2008: Vishnu Chaturvedi; Rama Ramani; Mahmoud A Ghannoum; Scott B Killian; Nicole Holliday; Cindy Knapp; Luis Ostrosky-Zeichner; Shawn A Messer; Michael A Pfaller; Naureen Iqbal; Beth A Arthington-Skaggs; Jose A Vazquez; Tin Sein; John H Rex; THOMAS WALSH
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.
Antimicrobial agents and chemotherapy 2008;52(4):1500-2.
2008: Michael A Pfaller; Daniel J Diekema; DL Gibbs; VA Newell; K P Ng; A Colombo; J Finquelievich; R Barnes; J Wadula
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Journal of clinical microbiology 2008;46(3):842-9.
2008: Michael J Klevay; Erika J Ernst; Jesse L Hollanbaugh; Joshua G Miller; Michael A Pfaller; Daniel J Diekema
Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Diagnostic microbiology and infectious disease 2008;60(3):273-7.
2008: Michael A Pfaller; Shawn A Messer; Linda Boyken; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
Journal of clinical microbiology 2008;46(2):551-9.
2008: Michael A Pfaller; Daniel J Diekema; DL Gibbs; VA Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Journal of clinical microbiology 2008;46(2):515-21.
2008: David Andes; D J Diekema; Michael A Pfaller; R A Prince; Karen Marchillo; J Ashbeck; J Hou
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Antimicrobial agents and chemotherapy 2008;52(2):539-50.
2008: Michael A Pfaller; Linda Boyken; Richard J Hollis; J Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Journal of clinical microbiology 2008;46(1):150-6.
2008: Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections.
Journal of clinical microbiology 2008;46(1):374-6.
2007: David Horn; Dionissios Neofytos; J Fishman; W Steinbach; E Anaisie; Kieren Marr; Michael A Pfaller; Ali S Olyaei
Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2007;26(12):907-14.
2007: David L Horn; Jay A Fishman; William J Steinbach; Elias J Anaissie; Kieren Marr; Ali S Olyaei; Michael A Pfaller; Mark A Weiss; Karen M Webster; Dionissios Neofytos
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
Diagnostic microbiology and infectious disease 2007;59(4):407-14.
2007: Xiaomin Zhao; Soon-Hwan Oh; Robert Jajko; Daniel J Diekema; Michael A Pfaller; Claude Pujol; David Soll; Lois L Hoyer
Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates.
Fungal genetics and biology : FG & B 2007;44(12):1298-309.
2007: Michael A Pfaller; Daniel J Diekema; G W Procop; Michael G Rinaldi
Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
Journal of clinical microbiology 2007;45(11):3522-8.
2007: Janet I Andrews; Diedre K Fleener; Shawn A Messer; Wendy F Hansen; Michael A Pfaller; Daniel J Diekema
The yeast connection: is Candida linked to breastfeeding associated pain?
American journal of obstetrics and gynecology 2007;197(4):424.e1-4.
2007: Werner E Bischoff; Brian K Tucker; Michelle L Wallis; Beth A Reboussin; Michael A Pfaller; Frederick G Hayden; Robert J Sherertz
Preventing the airborne spread of Staphylococcus aureus by persons with the common cold: effect of surgical scrubs, gowns, and masks.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2007;28(10):1148-54.
2007: Riina Rautemaa; Malcolm Richardson; Michael A Pfaller; Pirkko Koukila-Kähkölä; Jaakko Perheentupa; Harri Saxén
Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
The Journal of antimicrobial chemotherapy 2007;60(4):889-92.
2007: Ana Espinel-Ingroff; A Fothergill; Mahmoud Ghannoum; Elias K Manavathu; L Ostrosky-Zeichner; Michael A Pfaller; Michael G Rinaldi; W Schell; THOMAS WALSH
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.
Journal of clinical microbiology 2007;45(7):2180-2.
2007: Maiken Cavling Arendrup; David W Denning; Michael A Pfaller; D J Diekema; J H Rex
Does one voriconazole breakpoint suit all Candida species?
Journal of clinical microbiology 2007;45(6):2093; author reply 2094.
2007: Michael A Pfaller; Daniel J Diekema; DL Gibbs; VA Newell; Jacques Meis; I M Gould; W Fu; A L Colombo; E Rodriguez-Noriega
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Journal of clinical microbiology 2007;45(6):1735-45.
2007: Ana Espinel-Ingroff; Beth A Arthington-Skaggs; Naureen Iqbal; D Ellis; Michael A Pfaller; Shawn Messer; M Rinaldi; AW Fothergill; D L Gibbs; A Wang
Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
Journal of clinical microbiology 2007;45(6):1811-20.
2007: Daniel J Diekema; Shawn A Messer; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.
Journal of clinical microbiology 2007;45(6):1974-7.
2007: Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.
Journal of clinical microbiology 2007;45(4):1322-4.
2007: Michael A Pfaller; Helio S Sader; Ronald Jones
Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
Diagnostic microbiology and infectious disease 2007;57(4):459-65.
2007: Stan L Block; G V Doern; Michael A Pfaller
Oral beta-lactams in the treatment of acute otitis media.
Diagnostic microbiology and infectious disease 2007;57(3 Suppl):19S-30S.
2007: James A Hadley; Michael A Pfaller
Oral beta-lactams in the treatment of acute bacterial rhinosinusitis.
Diagnostic microbiology and infectious disease 2007;57(3 Suppl):47S-54S.
2007: Michael A Pfaller; Daniel J Diekema; G W Procop; Michael G Rinaldi
Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.
Journal of clinical microbiology 2007;45(3):796-802.
2007: Helio S Sader; Sujata M Bhavnani; Paul G Ambrose; RN Jones; Michael A Pfaller
Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci by applying contemporary in-vitro results and pharmacokinetic-pharmacodynamic principles.
Journal of chemotherapy (Florence, Italy) 2007;19(1):38-43.
2007: Shaoji Cheng; Cornelius J Clancy; Zongde Zhang; Binghua Hao; Wei Wang; Kenneth A Iczkowski; Michael A Pfaller; minh nguyen
Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue.
Cellular microbiology 2007;9(2):492-501.
2007: Michael A Pfaller; Daniel J Diekema
Epidemiology of invasive candidiasis: a persistent public health problem.
Clinical microbiology reviews 2007;20(1):133-63.
2007: Juan L Rodriguez-Tudela; J Peter Donnelly; Michael A Pfaller; Erja Chryssantou; Peter A Warn; David W Denning; Ana Espinel-Ingroff; Francesco Barchiesi; Manuel Cuenca Estrella
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2).
Journal of clinical microbiology 2007;45(1):109-11.
2007: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Journal of clinical microbiology 2007;45(1):70-5.
2006: Loreen A Herwaldt; Joseph J Cullen; David Scholz; Pamela French; M Bridget Zimmerman; Michael A Pfaller; Richard P Wenzel; Trish M Perl
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2006;27(12):1291-8.
2006: Mahmoud A Ghannoum; Beth A Arthington-Skaggs; V Chaturvedi; Ana Espinel-Ingroff; Michael A Pfaller; Robert P Rennie; M G Rinaldi; THOMAS WALSH
Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals.
Journal of clinical microbiology 2006;44(12):4353-6.
2006: Werner E Bischoff; Michelle L Wallis; Brian K Tucker; Beth A Reboussin; Michael A Pfaller; Frederick G Hayden; Robert J Sherertz
"Gesundheit!" sneezing, common colds, allergies, and Staphylococcus aureus dispersion.
The Journal of infectious diseases 2006;194(8):1119-26.
2006: Dionissios Neofytos; Michael A Pfaller; Daniel J Diekema; David Horn
A case of recurrent episodes of Candida parapsilosis fungemia.
Mycopathologia 2006;162(4):295-8.
2006: Michael A Pfaller; Daniel J Diekema; A L Colombo; C Kibbler; K P Ng; DL Gibbs; VA Newell
Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Journal of clinical microbiology 2006;44(10):3578-82.
2006: Michael A Pfaller; Daniel J Diekema; M Mendez; C Kibbler; P Erzsebet; S-C Chang; DL Gibbs; VA Newell
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Journal of clinical microbiology 2006;44(10):3551-6.
2006: Michael A Pfaller; Linda Boyken; Richard J Hollis; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
Journal of clinical microbiology 2006;44(10):3533-8.
2006: Michael A Pfaller; Deanna A Sutton
Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections.
Diagnostic microbiology and infectious disease 2006;56(2):147-52.
2006: Michael A Pfaller
Flavophospholipol use in animals: positive implications for antimicrobial resistance based on its microbiologic properties.
Diagnostic microbiology and infectious disease 2006;56(2):115-21.
2006: Michael A Pfaller; Helio S Sader; Thomas R Fritsche; Ronald Jones
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Diagnostic microbiology and infectious disease 2006;56(1):63-8.
2006: Santosh Katiyar; Michael A Pfaller; Thomas D Edlind
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
Antimicrobial agents and chemotherapy 2006;50(8):2892-4.
2006: Gregory T Siwek; Michael A Pfaller; Philip M Polgreen; Sandra Cobb; Peter Hoth; Margarida Magalheas-Silverman; Daniel J Diekema
Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Diagnostic microbiology and infectious disease 2006;55(3):209-12.
2006: Michael A Pfaller; Ronald Jones
Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003).
Archives of pathology & laboratory medicine 2006;130(6):767-78.
2006: Michael A Pfaller; John Segreti
Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42 Suppl 4():S153-63.
2006: Michael A Pfaller; Daniel J Diekema; Daniel J Sheehan
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
Clinical microbiology reviews 2006;19(2):435-47.
2006: Philip M Polgreen; Susan E Beekmann; Yi Yi Chen; G V Doern; Michael A Pfaller; Angela B Brueggemann; Loreen A Herwaldt; Daniel J Diekema
Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2006;27(3):252-6.
2006: Michael A Pfaller; Daniel J Diekema; John H Rex; Ana Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; Mahmoud A Ghannoum; F C Odds; Michael G Rinaldi; Daniel J Sheehan; P Troke; THOMAS WALSH; D W Warnock
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
Journal of clinical microbiology 2006;44(3):819-26.
2006: Michael A Pfaller; Linda Boyken; Richard J Hollis; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Journal of clinical microbiology 2006;44(3):760-3.
2006: Shawn A Messer; Daniel J Diekema; Linda Boyken; Shailesh Tendolkar; Richard J Hollis; Michael A Pfaller
Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Journal of clinical microbiology 2006;44(2):324-6.
2005: Michael A Pfaller
Antifungal susceptibility testing methods.
Current drug targets 2005;6(8):929-43.
2005: Michael A Pfaller; Daniel J Diekema; Michael G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; DL Gibbs
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
Journal of clinical microbiology 2005;43(12):5848-59.
2005: Michael A Pfaller; Linda Boyken; Richard J Hollis; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
Journal of clinical microbiology 2005;43(11):5425-7.
2005: Michael A Pfaller; Daniel J Diekema; Linda Boyken; Shawn A Messer; Shailesh Tendolkar; Richard J Hollis; B P Goldstein
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.
Antimicrobial agents and chemotherapy 2005;49(11):4795-7.
2005: Mark E Rupp; Steven J Lisco; Pamela A Lipsett; Trish M Perl; Kevin Keating; Joseph M Civetta; Leonard A Mermel; David Lee; E Patchen Dellinger; Michael Donahoe; David Giles; Michael A Pfaller; Dennis G Maki; Robert Sherertz
Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial.
Annals of internal medicine 2005;143(8):570-80.
2005: Ana Espinel-Ingroff; A Fothergill; Mahmoud Ghannoum; Elias K Manavathu; L Ostrosky-Zeichner; Michael A Pfaller; M Rinaldi; W Schell; THOMAS WALSH
Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole.
Journal of clinical microbiology 2005;43(10):5243-6.
2005: Michael A Pfaller; Linda Boyken; Shawn A Messer; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.
Journal of clinical microbiology 2005;43(10):5208-13.
2005: Elaine Blignaut; Julitha Molepo; Claude Pujol; David Soll; Michael A Pfaller
Clade-related amphotericin B resistance among South African Candida albicans isolates.
Diagnostic microbiology and infectious disease 2005;53(1):29-31.
2005: Ana Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; A Fothergill; Michael A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
Journal of clinical microbiology 2005;43(9):4535-40.
2005: A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; Michael A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Journal of clinical microbiology 2005;43(8):3884-9.
2005: Michael A Pfaller; Linda Boyken; Richard J Hollis; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
Journal of clinical microbiology 2005;43(8):3807-10.
2005: Michael Klevay; Alex Ebinger; Daniel Diekema; Shawn Messer; Richard J Hollis; Michael A Pfaller
Disk diffusion testing using Candida sp. colonies taken directly from CHROMagar Candida medium may decrease time required to obtain results.
Journal of clinical microbiology 2005;43(7):3497-9.
2005: Emmi Sarvikivi; Outi Lyytikäinen; David Soll; Claude Pujol; Michael A Pfaller; Malcolm Richardson; Pirkko Koukila-Kähkölä; Päivi Luukkainen; Harri Saxén
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit.
Journal of clinical microbiology 2005;43(6):2729-35.
2005: Kris P Heilmann; Cassie L Rice; Ashley L Miller; Norma J Miller; Susan E Beekmann; Michael A Pfaller; Sandra S Richter; G V Doern
Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States.
Antimicrobial agents and chemotherapy 2005;49(6):2561-4.
2005: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; G V Doern; Daniel J Diekema
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
Journal of clinical microbiology 2005;43(5):2163-7.
2005: Sandra S Richter; Rudolph P Galask; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller
Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.
Journal of clinical microbiology 2005;43(5):2155-62.
2005: Michael A Pfaller; Daniel J Diekema
Unusual fungal and pseudofungal infections of humans.
Journal of clinical microbiology 2005;43(4):1495-504.
2005: Andrew R Dodgson; Claude Pujol; Michael A Pfaller; David W Denning; David Soll
Evidence for recombination in Candida glabrata.
Fungal genetics and biology : FG & B 2005;42(3):233-43.
2005: Stefano Bassetti; Werner E Bischoff; Mark Walter; Barbara A Bassetti-Wyss; Lori Mason; Beth A Reboussin; Ralph B D'Agostino; Jack M Gwaltney; Michael A Pfaller; Robert J Sherertz
Dispersal of Staphylococcus aureus into the air associated with a rhinovirus infection.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2005;26(2):196-203.
2005: Daniel J Diekema; B Petroelje; Shawn A Messer; Richard J Hollis; Michael A Pfaller
Activities of available and investigational antifungal agents against rhodotorula species.
Journal of clinical microbiology 2005;43(1):476-8.
2004: Michael A Pfaller; Linda Boyken; Shawn A Messer; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species.
Journal of clinical microbiology 2004;42(11):4977-9.
2004: Suzane Silbert; Michael A Pfaller; Richard J Hollis; Afonso L Barth; Helio S Sader
Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2004;25(10):847-51.
2004: Michael A Pfaller; Linda Boyken; Richard J Hollis; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
Diagnostic microbiology and infectious disease 2004;50(2):113-7.
2004: Michael A Pfaller; Ana Espinel-Ingroff; Ronald Jones
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
Journal of clinical microbiology 2004;42(10):4577-80.
2004: Michael A Pfaller; Daniel J Diekema
Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
Journal of clinical microbiology 2004;42(10):4419-31.
2004: Michael A Pfaller
Anidulafungin: an echinocandin antifungal.
Expert opinion on investigational drugs 2004;13(9):1183-97.
2004: Greg T Siwek; Kirsty J Dodgson; Margarida De Magalhaes-Silverman; Luther A Bartelt; Sara B Kilborn; Peter L Hoth; Daniel J Diekema; Michael A Pfaller
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(4):584-7.
2004: Daniel J Diekema; Michael A Pfaller
Nosocomial candidemia: an ounce of prevention is better than a pound of cure.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2004;25(8):624-6.
2004: Michael A Pfaller; K C Hazen; Shawn A Messer; Linda Boyken; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.
Journal of clinical microbiology 2004;42(8):3607-12.
2004: Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
Journal of clinical microbiology 2004;42(8):3475-82.
2004: Michael A Pfaller; Shawn A Messer; Linda Boyken; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.
Journal of clinical microbiology 2004;42(7):3142-6.
2004: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp.
Journal of clinical microbiology 2004;42(7):3137-41.
2004: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.
Journal of clinical microbiology 2004;42(7):3117-9.
2004: Mahmoud A Ghannoum; V Chaturvedi; Ana Espinel-Ingroff; Michael A Pfaller; M G Rinaldi; Wendy Lee-Yang; David W Warnock
Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.
Journal of clinical microbiology 2004;42(7):2977-9.
2004: Daniel J Diekema; Kirsty J Dodgson; Bryndis Sigurdardottir; Michael A Pfaller
Rapid detection of antimicrobial-resistant organism carriage: an unmet clinical need.
Journal of clinical microbiology 2004;42(7):2879-83.
2004: Werner E Bischoff; Stefano Bassetti; Barbara A Bassetti-Wyss; Michelle L Wallis; Brian K Tucker; Beth A Reboussin; Ralph B D'Agostino; Michael A Pfaller; Jack M Gwaltney; Robert J Sherertz
Airborne dispersal as a novel transmission route of coagulase-negative staphylococci: interaction between coagulase-negative staphylococci and rhinovirus infection.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2004;25(6):504-11.
2004: Loreen A Herwaldt; Joseph J Cullen; Pamela French; Jianfang Hu; Michael A Pfaller; Richard P Wenzel; Trish M Perl
Preoperative risk factors for nasal carriage of Staphylococcus aureus.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2004;25(6):481-4.
2004: Erika J Ernst; Daniel J Diekema; Bonnie J BootsMiller; Thomas E Vaughn; Jon W Yankey; Stephen D Flach; Marcia M Ward; Carrie L J Franciscus; Elise Acosta; Michael A Pfaller; Bradley Doebbeling
Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data?
Diagnostic microbiology and infectious disease 2004;49(2):141-5.
2004: Andrew R Dodgson; Kirsty J Dodgson; Claude Pujol; Michael A Pfaller; David Soll
Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans.
Antimicrobial agents and chemotherapy 2004;48(6):2223-7.
2004: Vishnu Chaturvedi; Rama Ramani; Michael A Pfaller
Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans.
Journal of clinical microbiology 2004;42(5):2249-51.
2004: Michael A Pfaller; Daniel J Sheehan; John H Rex
Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.
Clinical microbiology reviews 2004;17(2):268-80.
2004: Michael A Pfaller; A Barry; J Bille; S Brown; D Ellis; Jacques Meis; Robert P Rennie; M Rinaldi; T Rogers; Maria M Traczewski
Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.
Journal of clinical microbiology 2004;42(4):1716-8.
2004: Michael A Pfaller; Shawn A Messer; Linda Boyken; Richard J Hollis; Cassie Rice; Shailesh Tendolkar; Daniel J Diekema
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
Diagnostic microbiology and infectious disease 2004;48(3):201-5.
2004: Michael A Pfaller; Linda Boyken; Shawn A Messer; Richard J Hollis; Daniel J Diekema
Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole.
Journal of clinical microbiology 2004;42(3):1288-9.
2004: Michael A Pfaller; Daniel J Diekema
Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10 Suppl 1():11-23.
2004: Michael A Pfaller; Daniel J Diekema; Shawn A Messer; Linda Boyken; Richard J Hollis; Ronald Jones
In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
Diagnostic microbiology and infectious disease 2004;48(2):101-5.
2004: Ana Espinel-Ingroff; Michael A Pfaller; Shawn A Messer; Cindy C Knapp; N Holliday; Scott B Killian
Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.
Journal of clinical microbiology 2004;42(2):718-21.
2004: Ana Gales; Michael A Pfaller; Helio S Sader; Richard J Hollis; Ronald Jones
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America.
Microbial drug resistance (Larchmont, N.Y.) 2004;10(4):286-91.
2004: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole.
Journal of clinical microbiology 2004;42(1):380-3.
2004: Wen-Liang Yu; Kuo-Chen Cheng; Lii-Tzu Wu; Michael A Pfaller; Patricia L Winokur; Ronald Jones
Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan.
Antimicrobial agents and chemotherapy 2004;48(1):362-3.
2004: Claude Pujol; Michael A Pfaller; David Soll
Flucytosine resistance is restricted to a single genetic clade of Candida albicans.
Antimicrobial agents and chemotherapy 2004;48(1):262-6.
2004: Daniel J Diekema; Bonnie J BootsMiller; Thomas E Vaughn; Robert F Woolson; Jon W Yankey; Erika J Ernst; Stephen D Flach; Marcia M Ward; Carrie L J Franciscus; Michael A Pfaller; Bradley Doebbeling
Antimicrobial resistance trends and outbreak frequency in United States hospitals.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(1):78-85.
2003: Suzane Silbert; Linda Boyken; Richard J Hollis; Michael A Pfaller
Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea.
Diagnostic microbiology and infectious disease 2003;47(4):619-21.
2003: Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Caspofungin activity against clinical isolates of fluconazole-resistant Candida.
Journal of clinical microbiology 2003;41(12):5729-31.
2003: Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen A Herwaldt; Michael A Pfaller; Daniel Diekema
Attributable mortality of nosocomial candidemia, revisited.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(9):1172-7.
2003: Aaron D Bossler; Sandra S Richter; A J Chavez; Scott A Vogelgesang; Deanna A Sutton; Amy M Grooters; Michael G Rinaldi; G S de Hoog; Michael A Pfaller
Exophiala oligosperma causing olecranon bursitis.
Journal of clinical microbiology 2003;41(10):4779-82.
2003: Stefano Bassetti; Robert J Sherertz; Michael A Pfaller
Airborne dispersal of Staphylococcus aureus associated with symptomatic rhinitis allergica.
Annals of internal medicine 2003;139(3):W-W60.
2003: Arnaldo Lopes Colombo; Analy S Azevedo Melo; Robert F Crespo Rosas; Reinaldo Salomão; Marcelo RS Briones; Richard J Hollis; Shawn A Messer; Michael A Pfaller
Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy.
Diagnostic microbiology and infectious disease 2003;46(4):253-7.
2003: Daniel J Diekema; Shawn A Messer; Richard J Hollis; Ronald Jones; Michael A Pfaller
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Journal of clinical microbiology 2003;41(8):3623-6.
2003: Ronald Jones; Michael A Pfaller
Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):708-12.
2003: A Barry; J Bille; S Brown; D Ellis; Jacques Meis; Michael A Pfaller; Robert P Rennie; M Rinaldi; T Rogers; Maria M Traczewski
Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.
Journal of clinical microbiology 2003;41(7):3410-2.
2003: Daniel J Diekema; Janet I Andrews; Holly Huynh; Paul R Rhomberg; Stella R Doktor; Jill Beyer; Virginia D Shortridge; Robert K Flamm; Ronald Jones; Michael A Pfaller
Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.
Journal of clinical microbiology 2003;41(6):2659-61.
2003: Michael A Pfaller; Shawn A Messer; Linda Boyken; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.
Journal of clinical microbiology 2003;41(5):2176-9.
2003: Michael A Pfaller; Daniel J Diekema; Linda Boyken; Shawn A Messer; Shailesh Tendolkar; Richard J Hollis
Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.
Journal of clinical microbiology 2003;41(5):1875-80.
2003: Michael A Pfaller; Shawn A Messer; Linda Boyken; Richard J Hollis; Daniel J Diekema
In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs.
Diagnostic microbiology and infectious disease 2003;45(4):241-4.
2003: Wen-Liang Yu; Lii-Tzu Wu; Michael A Pfaller; Patricia L Winokur; Ronald Jones
Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan.
Diagnostic microbiology and infectious disease 2003;45(4):221-4.
2003: Michael A Pfaller; Daniel J Diekema; Shawn A Messer; Linda Boyken; Richard J Hollis
Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Journal of clinical microbiology 2003;41(4):1440-6.
2003: Claude Pujol; Shawn A Messer; Michael A Pfaller; David Soll
Drug resistance is not directly affected by mating type locus zygosity in Candida albicans.
Antimicrobial agents and chemotherapy 2003;47(4):1207-12.
2003: J B Pfaller; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller
In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.
Journal of clinical microbiology 2003;41(3):1126-9.
2003: M J Maxwell; Shawn A Messer; Richard J Hollis; Linda Boyken; Shailesh Tendolkar; Daniel J Diekema; Michael A Pfaller
Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
Journal of clinical microbiology 2003;41(3):1087-90.
2003: Michael A Pfaller; Daniel J Diekema; Shawn A Messer; Richard J Hollis; Ronald Jones
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Antimicrobial agents and chemotherapy 2003;47(3):1068-71.
2003: Toshiaki Yamazumi; Michael A Pfaller; Shawn A Messer; AK Houston; Linda Boyken; Richard J Hollis; Itaru Furuta; Ronald Jones
Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
Journal of clinical microbiology 2003;41(1):267-72.
2003: M J Maxwell; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller
Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.
Journal of clinical microbiology 2003;41(1):97-9.
2003: Michael A Pfaller; Daniel J Diekema; Shawn A Messer; Linda Boyken; Richard J Hollis; Ronald Jones
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
Journal of clinical microbiology 2003;41(1):78-83.
2002: Daniel J Diekema; Michael A Pfaller; Ronald Jones
Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000.
International journal of antimicrobial agents 2002;20(6):412-8.
2002: Wen-Liang Yu; Ronald Jones; Richard J Hollis; Shawn A Messer; Douglas J Biedenbach; Lalitagauri M Deshpande; Michael A Pfaller
Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.
Journal of clinical microbiology 2002;40(12):4666-9.
2002: Erik L Munson; Michael A Pfaller; G V Doern
Modification of dienes mutual inhibition test for epidemiological characterization of Pseudomonas aeruginosa isolates.
Journal of clinical microbiology 2002;40(11):4285-8.
2002: Erik L Munson; Dennis R Troy; Joanne K Weber; Shawn A Messer; Michael A Pfaller
Presumptive identification of Candida kefyr on levine formulation of eosin methylene blue agar.
Journal of clinical microbiology 2002;40(11):4281-4.
2002: Michael A Pfaller; Shawn A Messer; Linda Boyken; Holly Huynh; Richard J Hollis; Daniel J Diekema
In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.
Antimicrobial agents and chemotherapy 2002;46(11):3518-21.
2002: John H Rex; Michael A Pfaller
Has antifungal susceptibility testing come of age?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(8):982-9.
2002: Elaine Blignaut; Shawn Messer; Richard J Hollis; Michael A Pfaller
Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals.
Diagnostic microbiology and infectious disease 2002;44(2):169-74.
2002: Shawn R Lockhart; Claude Pujol; Karla J Daniels; Matthew G Miller; Alexander D Johnson; Michael A Pfaller; David Soll
In Candida albicans, white-opaque switchers are homozygous for mating type.
Genetics 2002;162(2):737-45.
2002: Sarah L George; Jenny Gebhardt; Donna Klinzman; Mathew B Foster; Kevin D Patrick; Warren N Schmidt; Beth Alden; Michael A Pfaller; Jack T Stapleton
Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.
Journal of acquired immune deficiency syndromes (1999) 2002;31(2):154-62.
2002: Michael A Pfaller; Daniel J Diekema
Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.
Journal of clinical microbiology 2002;40(10):3551-7.
2002: Michael A Pfaller; Ronald Jones
Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Diagnostic microbiology and infectious disease 2002;44(1):77-84.
2002: Jan M Bell; John D Turnidge; Michael A Pfaller; Ronald Jones
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
Diagnostic microbiology and infectious disease 2002;43(4):315-8.
2002: Jeffrey T Kirby; Alan H Mutnick; Ronald Jones; Douglas J Biedenbach; Michael A Pfaller
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
Diagnostic microbiology and infectious disease 2002;43(4):303-9.
2002: Claude Pujol; Michael A Pfaller; David Soll
Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade.
Journal of clinical microbiology 2002;40(8):2729-40.
2002: Ronald Jones; Jeffrey T Kirby; Mondell L Beach; Douglas J Biedenbach; Michael A Pfaller
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;43(3):239-43.
2002: John E Sutphin; Michael A Pfaller; Richard J Hollis; Michael D Wagoner
Donor-to-host transmission of Candida albicans after corneal transplantation.
American journal of ophthalmology 2002;134(1):120-1.
2002: Sandra S Richter; Susan E Beekmann; J L Croco; Daniel J Diekema; FP Koontz; Michael A Pfaller; G V Doern
Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm.
Journal of clinical microbiology 2002;40(7):2437-44.
2002: Trish M Perl; Joseph J Cullen; Richard P Wenzel; M Bridget Zimmerman; Michael A Pfaller; Deborah Sheppard; Jennifer Twombley; Pamela P French; Loreen A Herwaldt
Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.
The New England journal of medicine 2002;346(24):1871-7.
2002: Arthur L Barry; Michael A Pfaller; Robert P Rennie; Peter C Fuchs; Steven D Brown
Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods.
Antimicrobial agents and chemotherapy 2002;46(6):1781-4.
2002: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Ronald Jones; Daniel J Diekema
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
Antimicrobial agents and chemotherapy 2002;46(6):1723-7.
2002: Ellen E Roling; Michael E Klepser; Ashley Wasson; Russell Lewis; Erika J Ernst; Michael A Pfaller
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
Diagnostic microbiology and infectious disease 2002;43(1):13-7.
2002: Michael A Pfaller; Ronald Jones
Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000.
International journal of antimicrobial agents 2002;19(5):383-8.
2002: Kelley A Gordon; Michael A Pfaller; Ronald Jones
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
The Journal of antimicrobial chemotherapy 2002;49(5):851-5.
2002: Wen-Liang Yu; Michael A Pfaller; Patricia L Winokur; Ronald Jones
Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.
Emerging infectious diseases 2002;8(5):522-4.
2002: Connie S Price; Holly Huynh; Suzanne Paule; Richard J Hollis; Gary A Noskin; Michael A Pfaller; Lance R Peterson
Comparison of an automated ribotyping system to restriction endonuclease analysis and pulsed-field gel electrophoresis for differentiating vancomycin-resistant Enterococcus faecium isolates.
Journal of clinical microbiology 2002;40(5):1858-61.
2002: Michael A Pfaller; Daniel J Diekema; Shawn A Messer; Linda Boyken; Holly Huynh; Richard J Hollis
Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.
Journal of clinical microbiology 2002;40(5):1694-7.
2002: Nancy B McClenny; Haihua Fei; Ellen J Baron; Ana Gales; Allison Houston; Richard J Hollis; Michael A Pfaller
Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance.
Antimicrobial agents and chemotherapy 2002;46(5):1325-8.
2002: Lalitagauri M Deshpande; A M Fix; Michael A Pfaller; Ronald Jones
Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.
Diagnostic microbiology and infectious disease 2002;42(4):283-90.
2002: Tige R Rustad; David A Stevens; Michael A Pfaller; Theodore C White
Homozygosity at the Candida albicans MTL locus associated with azole resistance.
Microbiology (Reading, England) 2002;148(Pt 4):1061-72.
2002: Daniel J Diekema; Shawn A Messer; Angela B Brueggemann; Stacy Coffman; G V Doern; Loreen A Herwaldt; Michael A Pfaller
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.
Journal of clinical microbiology 2002;40(4):1298-302.
2002: Wen-Liang Yu; Patricia L Winokur; Diana L Von Stein; Michael A Pfaller; Jen Hsien Wang; Ronald Jones
First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan.
Antimicrobial agents and chemotherapy 2002;46(4):1098-100.
2002: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Ronald Jones
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Antimicrobial agents and chemotherapy 2002;46(4):1032-7.
2002: Erik L Munson; Michael A Pfaller; FP Koontz; G V Doern
Comparison of porphyrin-based, growth factor-based, and biochemical-based testing methods for identification of Haemophilus influenzae.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2002;21(3):196-203.
2002: Ronald Jones; Michael A Pfaller
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?
Diagnostic microbiology and infectious disease 2002;42(3):213-5.
2002: Jan M Bell; John D Turnidge; Ana Gales; Michael A Pfaller; Ronald Jones
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).
Diagnostic microbiology and infectious disease 2002;42(3):193-8.
2002: Michael A Pfaller; Daniel J Diekema; Ronald Jones; Shawn A Messer; Richard J Hollis
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.
Journal of clinical microbiology 2002;40(3):852-6.
2002: Stefan Weber; Loreen A Herwaldt; louise-anne mcnutt; Paul R Rhomberg; Pierre Vaudaux; Michael A Pfaller; Trish M Perl
An outbreak of Staphylococcus aureus in a pediatric cardiothoracic surgery unit.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2002;23(2):77-81.
2002: Michael A Pfaller; Mondell L Beach; Kelley A Gordon; Ronald Jones
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons.
Journal of chemotherapy (Florence, Italy) 2002;14(1):13-8.
2002: Ronald Jones; Michael A Pfaller; Paul R Rhomberg; Donald H Walter
Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods.
Journal of clinical microbiology 2002;40(2):461-5.
2002: Russell Lewis; D J Diekema; S A Messer; Michael A Pfaller; Michael E Klepser
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species.
The Journal of antimicrobial chemotherapy 2002;49(2):345-51.
2002: Sandra S Richter; Kris P Heilmann; Stacy Coffman; HK Huynh; Angela B Brueggemann; Michael A Pfaller; G V Doern
The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(3):330-9.
2001: Michael A Pfaller; A F Ehrhardt; Ronald Jones
Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
The American journal of medicine 2001;111 Suppl 9A():4S-12S; discussion 36S-38S.
2001: Michael A Pfaller; W L Yu
Antifungal susceptibility testing. New technology and clinical applications.
Infectious disease clinics of North America 2001;15(4):1227-61.
2001: Michael A Pfaller; Ronald Jones; Douglas J Biedenbach
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).
Diagnostic microbiology and infectious disease 2001;41(4):177-82.
2001: Lisa Saiman; E Ludington; J D Dawson; Jan Patterson; S Rangel-Frausto; RT Wiblin; Henry M Blumberg; Michael A Pfaller; M Rinaldi; John Edwards; Richard P Wenzel; William R Jarvis
Risk factors for Candida species colonization of neonatal intensive care unit patients.
The Pediatric infectious disease journal 2001;20(12):1119-24.
2001: Michael A Pfaller; Shawn A Messer; K Mills; A Bolmström; Ronald Jones
Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.
Journal of clinical microbiology 2001;39(12):4387-9.
2001: Kelley A Gordon; J Fusco; Douglas J Biedenbach; Michael A Pfaller; Ronald Jones
Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2001;45(12):3599-600.
2001: Bradley E Britigan; R A Miller; D J Hassett; Michael A Pfaller; Michael L McCormick; George T Rasmussen
Antioxidant enzyme expression in clinical isolates of Pseudomonas aeruginosa: identification of an atypical form of manganese superoxide dismutase.
Infection and immunity 2001;69(12):7396-401.
2001: Ronald Jones; Mondell L Beach; Michael A Pfaller
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Diagnostic microbiology and infectious disease 2001;41(3):161-3.
2001: Michael A Pfaller; Shawn A Messer; K Mills; A Bolmström; Ronald Jones
Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.
Journal of clinical microbiology 2001;39(11):3952-4.
2001: Mary E Brandt; Michael A Pfaller; Rana A Hajjeh; Richard J Hamill; Peter G Pappas; Arthur Reingold; David Rimland; David W Warnock
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
Antimicrobial agents and chemotherapy 2001;45(11):3065-9.
2001: John H Rex; Michael A Pfaller; THOMAS WALSH; V Chaturvedi; Ana Espinel-Ingroff; Mahmoud A Ghannoum; L L Gosey; F C Odds; Michael G Rinaldi; Daniel J Sheehan; D W Warnock
Antifungal susceptibility testing: practical aspects and current challenges.
Clinical microbiology reviews 2001;14(4):643-58, table of contents.
2001: Toshiaki Yamazumi; Itaru Furuta; Daniel J Diekema; Michael A Pfaller; Ronald Jones
Comparison of the Vitek gram-positive susceptibility 106 card, the MRSA-Screen latex agglutination test, and mecA analysis for detecting oxacillin resistance in a geographically diverse collection of clinical isolates of coagulase-negative staphylococci.
Journal of clinical microbiology 2001;39(10):3633-6.
2001: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Ronald Jones
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Antimicrobial agents and chemotherapy 2001;45(10):2862-4.
2001: Sandra S Richter; Kelley A Gordon; Paul R Rhomberg; Michael A Pfaller; Ronald Jones
Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99.
Diagnostic microbiology and infectious disease 2001;41(1-2):83-8.
2001: Ronald Jones; Michael A Pfaller; M R Jacobs; P C Appelbaum; P C Fuchs
Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
Diagnostic microbiology and infectious disease 2001;41(1-2):1-14.
2001: Michael A Pfaller; D J Diekema; Ronald Jones; Helio S Sader; A C Fluit; Richard J Hollis; S A Messer
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Journal of clinical microbiology 2001;39(9):3254-9.
2001: Helio S Sader; Ana Gales; Michael A Pfaller; Rodrigo E Mendes; C Zoccoli; A Barth; Ronald Jones
Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2001;5(4):200-14.
2001: A M Fix; Michael A Pfaller; Douglas J Biedenbach; Mondell L Beach; Ronald Jones
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.
International journal of antimicrobial agents 2001;18(2):141-5.
2001: Holly L Hoffman; Michael A Pfaller
In vitro antifungal susceptibility testing.
Pharmacotherapy 2001;21(8 Pt 2):111S-123S.
2001: Henry M Blumberg; William R Jarvis; J Michael Soucie; John Edwards; Jan Patterson; Michael A Pfaller; MS Rangel-Frausto; Michael G Rinaldi; Lisa Saiman; RT Wiblin; Richard P Wenzel
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(2):177-86.
2001: D Mathai; Ronald Jones; Michael A Pfaller
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).
Diagnostic microbiology and infectious disease 2001;40(3):129-36.
2001: Ronald Jones; D J Biedenbach; D M Johnson; Michael A Pfaller
In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.
Journal of chemotherapy (Florence, Italy) 2001;13(3):244-54.
2001: Ana Espinel-Ingroff; M Bartlett; V Chaturvedi; Mahmoud Ghannoum; K C Hazen; Michael A Pfaller; M Rinaldi; THOMAS WALSH
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.
Antimicrobial agents and chemotherapy 2001;45(6):1828-35.
2001: Michael A Pfaller; J Acar; Ronald Jones; Jan Verhoef; J Turnidge; Helio S Sader
Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S156-67.
2001: Daniel J Diekema; Michael A Pfaller; F J Schmitz; Jorgelina Smayevsky; J Bell; Ronald Jones; M Beach
Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S114-32.
2001: Michael A Pfaller; Ronald Jones; D H Walter
Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin.
Diagnostic microbiology and infectious disease 2001;40(1-2):67-70.
2001: W Michael Dunne; K S Kehl; C A Holland-Staley; AB Brueggemann; Michael A Pfaller; G V Doern
Comparison of results generated by serotyping, pulsed-field restriction analysis, ribotyping, and repetitive-sequence PCR used to characterize penicillin-resistant pneumococci from the United States.
Journal of clinical microbiology 2001;39(5):1791-5.
2001: Lalitagauri M Deshpande; Ronald Jones; Michael A Pfaller
Accuracy of broth microdilution and E test methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999).
Diagnostic microbiology and infectious disease 2001;39(4):267-9.
2001: Douglas J Biedenbach; Ronald Jones; Michael A Pfaller
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Diagnostic microbiology and infectious disease 2001;39(4):245-50.
2001: Ronald Jones; Michael A Pfaller
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Diagnostic microbiology and infectious disease 2001;39(4):237-43.
2001: Daniel J Diekema; Mondell L Beach; Michael A Pfaller; Ronald Jones
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7(3):152-7.
2001: Michael A Pfaller
Molecular approaches to diagnosing and managing infectious diseases: practicality and costs.
Emerging infectious diseases 2001;7(2):312-8.
2001: Michael A Pfaller; Ronald Jones
Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Postgraduate medicine 2001;109(2 Suppl):10-21.
2001: Ronald Jones; Michael A Pfaller; M Stilwell
Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
Diagnostic microbiology and infectious disease 2001;39(2):133-5.
2001: Ana Gales; Douglas J Biedenbach; Patricia L Winokur; D M Hacek; Michael A Pfaller; Ronald Jones
Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme.
Diagnostic microbiology and infectious disease 2001;39(2):125-7.
2001: D Mathai; MT Lewis; KC Kugler; Michael A Pfaller; Ronald Jones
Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).
Diagnostic microbiology and infectious disease 2001;39(2):105-16.
2001: L Enger; Sophie Joly; Claude Pujol; P Simonson; Michael A Pfaller; David Soll
Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis.
Journal of clinical microbiology 2001;39(2):658-69.
2001: Angela B Brueggemann; Michael A Pfaller; G V Doern
Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae.
Journal of clinical microbiology 2001;39(1):367-9.
2001: Toshiaki Yamazumi; SA Marshall; Werner W Wilke; Daniel J Diekema; Michael A Pfaller; Ronald Jones
Comparison of the Vitek Gram-Positive Susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus.
Journal of clinical microbiology 2001;39(1):53-6.
2000: Y F Berrouane; louise-anne mcnutt; BJ Buschelman; Paul R Rhomberg; M D Sanford; Richard J Hollis; Michael A Pfaller; Loreen A Herwaldt
Outbreak of severe Pseudomonas aeruginosa infections caused by a contaminated drain in a whirlpool bathtub.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(6):1331-7.
2000: Ronald Jones; Michael A Pfaller
Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).
Journal of clinical microbiology 2000;38(11):4298-9.
2000: Ronald Jones; Michael A Pfaller
Potencies of newer fluoroquinolones against Viridans group Streptococciisolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada!
Antimicrobial agents and chemotherapy 2000;44(10):2922-3.
2000: Helio S Sader; Ana Gales; T D Granacher; Michael A Pfaller; Ronald Jones
Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2000;4(5):245-54.
2000: Janet I Andrews; Daniel J Diekema; Stephen K Hunter; Paul R Rhomberg; Michael A Pfaller; Ronald Jones; G V Doern
Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.
American journal of obstetrics and gynecology 2000;183(4):859-62.
2000: Michael A Pfaller; Shawn A Messer; AK Houston; K Mills; A Bolmstrom; Ronald Jones
Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
Journal of clinical microbiology 2000;38(10):3715-7.
2000: Kaaren G Vargas; Shawn A Messer; Michael A Pfaller; Shawn R Lockhart; Jack T Stapleton; John W Hellstein; David Soll
Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive individuals prior to first thrush episode.
Journal of clinical microbiology 2000;38(10):3595-607.
2000: S M Gunderson; Henry Hoffman; Erika J Ernst; Michael A Pfaller; Michael E Klepser
In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect.
Antimicrobial agents and chemotherapy 2000;44(10):2887-90.
2000: Toshiaki Yamazumi; Michael A Pfaller; Shawn A Messer; AK Houston; Richard J Hollis; Ronald Jones
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.
Antimicrobial agents and chemotherapy 2000;44(10):2883-6.
2000: Patricia L Winokur; Angela B Brueggemann; D L DeSalvo; L Hoffmann; M D Apley; E K Uhlenhopp; Michael A Pfaller; G V Doern
Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase.
Antimicrobial agents and chemotherapy 2000;44(10):2777-83.
2000: Michael A Pfaller; Ronald Jones
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
The Journal of antimicrobial chemotherapy 2000;46 Suppl T2():25-37.
2000: Hilmar Wisplinghoff; Michael B Edmond; Michael A Pfaller; Ronald Jones; Richard P Wenzel; Harald Seifert
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(3):690-7.
2000: Arthur L Barry; Michael A Pfaller; Steven D Brown; Ana Espinel-Ingroff; M A Ghannoum; C Knapp; Robert P Rennie; J H Rex; M G Rinaldi
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.
Journal of clinical microbiology 2000;38(9):3457-9.
2000: Michael A Pfaller; Shawn A Messer; K Mills; A Bolmström
In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs.
Journal of clinical microbiology 2000;38(9):3359-61.
2000: Michael A Pfaller
Epidemiology of nosocomial candidiasis: the importance of molecular typing.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2000;4(4):161-7.
2000: Ronald Jones; Michael A Pfaller
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31 Suppl 2():S16-23.
2000: L Deshpande; Michael A Pfaller; Ronald Jones
In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum beta-lactamase producing strains.
International journal of antimicrobial agents 2000;15(4):271-5.
2000: Ronald Jones; Michael A Pfaller; M E Erwin
Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas.
International journal of antimicrobial agents 2000;15(3):227-30.
2000: Michael E Klepser; D Malone; Russell Lewis; Erika J Ernst; Michael A Pfaller
Evaluation of voriconazole pharmacodynamics using time-kill methodology.
Antimicrobial agents and chemotherapy 2000;44(7):1917-20.
2000: Ronald Jones; S G Jenkins; D J Hoban; Michael A Pfaller; R Ramphal
In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
International journal of antimicrobial agents 2000;15(2):111-8.
2000: Ronald Jones; MA Croco; KC Kugler; Michael A Pfaller; Mondell L Beach
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).
Diagnostic microbiology and infectious disease 2000;37(2):115-25.
2000: DM Johnson; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller; Ronald Jones
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Diagnostic microbiology and infectious disease 2000;37(2):99-105.
2000: Ronald Jones; S G Jenkins; D J Hoban; Michael A Pfaller; R Ramphal
In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Diagnostic microbiology and infectious disease 2000;37(2):93-8.
2000: MT Lewis; Ana Gales; Helio S Sader; Michael A Pfaller; Ronald Jones
Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998).
Diagnostic microbiology and infectious disease 2000;37(1):63-74.
2000: Michael A Pfaller
Antifungal susceptibility testing: progress and future developments.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2000;4(2):55-60.
2000: Lisa Saiman; E Ludington; Michael A Pfaller; S Rangel-Frausto; RT Wiblin; J Dawson; Henry M Blumberg; Jan Patterson; M Rinaldi; John Edwards; Richard P Wenzel; William R Jarvis
Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group.
The Pediatric infectious disease journal 2000;19(4):319-24.
2000: Erika J Ernst; Michael E Klepser; Michael A Pfaller
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
Antimicrobial agents and chemotherapy 2000;44(4):1108-11.
2000: Ana Gales; Ronald Jones; Kelley A Gordon; Helio S Sader; Werner W Wilke; Mondell L Beach; Michael A Pfaller; G V Doern
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).
The Journal of antimicrobial chemotherapy 2000;45(3):295-303.
2000: Michael A Pfaller; I Mujeeb; Richard J Hollis; Ronald Jones; G V Doern
Evaluation of the discriminatory powers of the Dienes test and ribotyping as typing methods for Proteus mirabilis.
Journal of clinical microbiology 2000;38(3):1077-80.
2000: Michael A Pfaller; Ronald Jones; G V Doern; Helio S Sader; Shawn A Messer; AK Houston; Stacy Coffman; Richard J Hollis
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.
Antimicrobial agents and chemotherapy 2000;44(3):747-51.
2000: Patricia L Winokur; M V Eidelstain; OU Stetsiouk; Leonid S Stratchounski; J Blahova; G K Reshedko; MA Croco; Richard J Hollis; Michael A Pfaller; Ronald Jones
Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2000;6(2):103-8.
2000: CJ Jessup; Guadalupe H Reyes; A Fothergill; D McCarthy; M Rinaldi; Shawn Messer; Michael A Pfaller; Mahmoud Ghannoum
A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study.
Journal of chemotherapy (Florence, Italy) 2000;12(1):22-9.
2000: Daniel J Diekema; Michael A Pfaller; Ronald Jones; G V Doern; KC Kugler; Mondell L Beach; Helio S Sader
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.
International journal of antimicrobial agents 2000;13(4):257-71.
2000: Reuben Ramphal; D J Hoban; Michael A Pfaller; Ronald Jones
Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Diagnostic microbiology and infectious disease 2000;36(2):125-9.
2000: Russell Lewis; Michael E Klepser; Michael A Pfaller
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods.
Diagnostic microbiology and infectious disease 2000;36(2):101-5.
2000: Daniel J Diekema; Michael A Pfaller; J Turnidge; Jan Verhoef; J Bell; A C Fluit; G V Doern; Ronald Jones
Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998.
Microbial drug resistance (Larchmont, N.Y.) 2000;6(3):213-21.
2000: Ana Gales; Kelley A Gordon; Werner W Wilke; Michael A Pfaller; Ronald Jones
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
Diagnostic microbiology and infectious disease 2000;36(1):61-4.
2000: Ana Gales; Ronald Jones; Michael A Pfaller; Kelley A Gordon; Helio S Sader
Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2000;4(2):75-84.
1999: MS Rangel-Frausto; Paul R Rhomberg; Richard J Hollis; Michael A Pfaller; Richard P Wenzel; C M Helms; Loreen A Herwaldt
Persistence of Legionella pneumophila in a hospital's water system: a 13-year survey.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1999;20(12):793-7.
1999: Ana Gales; Michael A Pfaller; AK Houston; Sophie Joly; Derek Sullivan; David C Coleman; David Soll
Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems.
Journal of clinical microbiology 1999;37(12):3804-8.
1999: Michael A Pfaller; Ronald Jones; G V Doern; Juan C Salazar
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(3):235-41.
1999: Ronald Jones; ME Erwin; Douglas J Biedenbach; DM Johnson; Michael A Pfaller
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
Diagnostic microbiology and infectious disease 1999;35(3):227-34.
1999: Michael A Pfaller
Molecular epidemiology in the care of patients.
Archives of pathology & laboratory medicine 1999;123(11):1007-10.
1999: A S Kao; Mary E Brandt; W R Pruitt; Laura Conn; Bradley A Perkins; David S Stephens; Wendy Baughman; Arthur Reingold; Gretchen Rothrock; Michael A Pfaller; Robert W Pinner; Rana A Hajjeh
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(5):1164-70.
1999: Michael A Pfaller; Ronald Jones; G V Doern
Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(2):153-8.
1999: Daniel J Diekema; Michael A Pfaller; Ronald Jones; G V Doern; Patricia L Winokur; Ana Gales; Helio S Sader; KC Kugler; M Beach
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(3):595-607.
1999: BJ Buschelman; Ronald Jones; Michael A Pfaller; FP Koontz; G V Doern
Colony morphology of Candida spp. as a guide to species identification.
Diagnostic microbiology and infectious disease 1999;35(1):89-91.
1999: Michael A Pfaller; V Korten; Ronald Jones; G V Doern
Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(1):65-73.
1999: Ronald Jones; KC Kugler; Michael A Pfaller; Patricia L Winokur
Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.
Diagnostic microbiology and infectious disease 1999;35(1):55-63.
1999: Michael A Pfaller; Ronald Jones; G V Doern; A C Fluit; Jan Verhoef; Helio S Sader; Shawn A Messer; AK Houston; Stacy Coffman; Richard J Hollis
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).
Diagnostic microbiology and infectious disease 1999;35(1):19-25.
1999: Daniel J Diekema; Michael A Pfaller; Shawn A Messer; AK Houston; Richard J Hollis; G V Doern; Ronald Jones
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.
Antimicrobial agents and chemotherapy 1999;43(9):2236-9.
1999: F Marco; Shawn R Lockhart; Michael A Pfaller; Claude Pujol; MS Rangel-Frausto; T Wiblin; Henry M Blumberg; John Edwards; William R Jarvis; Lisa Saiman; Jan Patterson; Michael G Rinaldi; Richard P Wenzel; David Soll
Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3.
Journal of clinical microbiology 1999;37(9):2817-28.
1999: MS Rangel-Frausto; T Wiblin; Henry M Blumberg; Lisa Saiman; Jan Patterson; M Rinaldi; Michael A Pfaller; John Edwards; William R Jarvis; J Dawson; Richard P Wenzel
National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(2):253-8.
1999: Michael B Edmond; S E Wallace; Donna K McClish; Michael A Pfaller; Ronald Jones; Richard P Wenzel
Nosocomial bloodstream infections in United States hospitals: a three-year analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(2):239-44.
1999: Richard J Hollis; J L Bruce; S J Fritschel; Michael A Pfaller
Comparative evaluation of an automated ribotyping instrument versus pulsed-field gel electrophoresis for epidemiological investigation of clinical isolates of bacteria.
Diagnostic microbiology and infectious disease 1999;34(4):263-8.
1999: D Shen; D J Biedenbach; P L Winokur; Michael A Pfaller; Ronald Jones
Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases.
Diagnostic microbiology and infectious disease 1999;34(3):159-64.
1999: S A Marshall; Michael A Pfaller; Ronald Jones
Ability of the modified Vitek card to detect coagulase-negative staphylococcal with mecA and Oxacillin-resistant phenotypes.
Journal of clinical microbiology 1999;37(6):2122-3.
1999: Ronald Jones; DM Johnson; ME Erwin; Mondell L Beach; Douglas J Biedenbach; Michael A Pfaller
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):91-8.
1999: Ronald Jones; Douglas J Biedenbach; ME Erwin; Mondell L Beach; Michael A Pfaller
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Journal of clinical microbiology 1999;37(6):1999-2002.
1999: G V Doern; Ronald Jones; Michael A Pfaller; KC Kugler; Mondell L Beach
Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America).
Diagnostic microbiology and infectious disease 1999;34(1):65-72.
1999: J C Seguin; Robert D Walker; John P Caron; Wesley E Kloos; Carol G George; Richard J Hollis; Ronald Jones; Michael A Pfaller
Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission.
Journal of clinical microbiology 1999;37(5):1459-63.
1999: G V Doern; Angela B Brueggemann; Michael A Pfaller; Ronald Jones
Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program.
Archives of pathology & laboratory medicine 1999;123(4):285-9.
1999: Michael A Pfaller; Ronald Jones; G V Doern; Helio S Sader; KC Kugler; Mondell L Beach
Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.
Diagnostic microbiology and infectious disease 1999;33(4):283-97.
1999: Ronald Jones; KC Kugler; ME Erwin; Douglas J Biedenbach; Mondell L Beach; Michael A Pfaller
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;33(4):247-53.
1999: Ana Espinel-Ingroff; Jose A Vazquez; Dina Boikov; Michael A Pfaller
Evaluation of DNA-based typing procedures for strain categorization of Candida spp.
Diagnostic microbiology and infectious disease 1999;33(4):231-9.
1999: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Ronald Jones; G V Doern; Mary E Brandt; RA Hajjeh
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
Diagnostic microbiology and infectious disease 1999;33(4):217-22.
1999: S Richter; M G Cormican; Michael A Pfaller; C K Lee; R Gingrich; M G Rinaldi; D A Sutton
Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature.
Journal of clinical microbiology 1999;37(4):1154-60.
1999: C Wendt; Shawn A Messer; Richard J Hollis; Michael A Pfaller; Richard P Wenzel; Loreen A Herwaldt
Recurrent gram-negative bacteremia: incidence and clinical patterns.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(3):611-7.
1999: C Wendt; Shawn A Messer; Richard J Hollis; Michael A Pfaller; Richard P Wenzel; Loreen A Herwaldt
Molecular epidemiology of gram-negative bacteremia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(3):605-10.
1999: Michael A Pfaller; Shawn A Messer; S Gee; Sophie Joly; Claude Pujol; Derek Sullivan; David C Coleman; David Soll
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Journal of clinical microbiology 1999;37(3):870-2.
1999: Ana Espinel-Ingroff; Michael A Pfaller; Shawn A Messer; Cindy C Knapp; Scott B Killian; HA Norris; Mahmoud A Ghannoum
Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
Journal of clinical microbiology 1999;37(3):591-5.
1999: Y F Berrouane; Loreen A Herwaldt; Michael A Pfaller
Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.
Journal of clinical microbiology 1999;37(3):531-7.
1999: Jack T Stapleton; Donna Klinzman; Warren N Schmidt; Michael A Pfaller; P Wu; Douglas R LaBrecque; J q Han; MJ Phillips; Robert F Woolson; B Alden
Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA.
Journal of clinical microbiology 1999;37(3):484-9.
1999: Ronald Jones; Donald E Low; Michael A Pfaller
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Diagnostic microbiology and infectious disease 1999;33(2):101-12.
1999: Erika J Ernst; Michael E Klepser; Michael E Ernst; Shawn A Messer; Michael A Pfaller
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.
Diagnostic microbiology and infectious disease 1999;33(2):75-80.
1999: Trish M Perl; W A Krüger; A Houston; Linda Boyken; Michael A Pfaller; Loreen A Herwaldt
Investigation of suspected nosocomial clusters of Staphylococcus haemolyticus infections.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1999;20(2):128-31.
1999: G V Doern; Ronald Jones; Michael A Pfaller; KC Kugler
Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).
Antimicrobial agents and chemotherapy 1999;43(2):385-9.
1999: Michael A Pfaller; J Zhang; Shawn A Messer; Mary E Brandt; RA Hajjeh; CJ Jessup; M Tumberland; EK Mbidde; Mahmoud A Ghannoum
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
Antimicrobial agents and chemotherapy 1999;43(1):169-71.
1998: F Marco; Michael A Pfaller; Shawn A Messer; Ronald Jones
Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Medical mycology : official publication of the International Society for Human and Animal Mycology 1998;36(6):433-6.
1998: G V Doern; Michael A Pfaller; ME Erwin; Angela B Brueggemann; Ronald Jones
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 1998;32(4):313-6.
1998: Helio S Sader; Ronald Jones; Ana Gales; Patricia L Winokur; KC Kugler; Michael A Pfaller; G V Doern
Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group.
Diagnostic microbiology and infectious disease 1998;32(4):289-301.
1998: Michael E Klepser; Russell Lewis; Michael A Pfaller
Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options.
The Annals of pharmacotherapy 1998;32(12):1353-61.
1998: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Ronald Jones; G V Doern; Mary E Brandt; RA Hajjeh
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Antimicrobial agents and chemotherapy 1998;42(12):3242-4.
1998: Michael E Klepser; Michael A Pfaller
Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994.
Journal of clinical microbiology 1998;36(12):3653-6.
1998: Ronald Jones; Mondell L Beach; Michael A Pfaller; G V Doern
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Diagnostic microbiology and infectious disease 1998;32(3):247-52.
1998: Michael A Pfaller; Shawn A Messer; A Bolmström
Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B.
Diagnostic microbiology and infectious disease 1998;32(3):223-7.
1998: Erika J Ernst; Michael E Klepser; Michael A Pfaller
In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time.
Diagnostic microbiology and infectious disease 1998;32(3):205-10.
1998: Michael A Pfaller; J Zhang; Shawn Messer; M Tumberland; EK Mbidde; CJ Jessup; Mahmoud Ghannoum
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Diagnostic microbiology and infectious disease 1998;32(3):191-9.
1998: MA Croco; Douglas J Biedenbach; Michael A Pfaller; G V Doern; Ronald Jones
In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
The Journal of antimicrobial chemotherapy 1998;42(5):672-3.
1998: Michael A Pfaller
The epidemiology of invasive mycoses--narrowing the gap.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(5):1148-50.
1998: C Savor; Michael A Pfaller; JA Kruszynski; Richard J Hollis; Gary A Noskin; Lance R Peterson
Comparison of genomic methods for differentiating strains of Enterococcus faecium: assessment using clinical epidemiologic data.
Journal of clinical microbiology 1998;36(11):3327-31.
1998: J R DiPersio; Ronald Jones; T Barrett; G V Doern; Michael A Pfaller
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).
Diagnostic microbiology and infectious disease 1998;32(2):131-5.
1998: Ronald Jones; Michael A Pfaller; G V Doern
Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Diagnostic microbiology and infectious disease 1998;32(2):119-26.
1998: Ronald Jones; Douglas J Biedenbach; SA Marshall; Michael A Pfaller; G V Doern
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
Diagnostic microbiology and infectious disease 1998;32(2):107-10.
1998: D M Johnson; Ronald Jones; Michael A Pfaller
Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
The Journal of antimicrobial chemotherapy 1998;42(4):557-9.
1998: P Vigeant; Vivian G Loo; C Bertrand; C Dixon; R Hollis; Michael A Pfaller; A P McLean; D J Briedis; Trish M Perl; HG Robson
An outbreak of Serratia marcescens infections related to contaminated chlorhexidine.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1998;19(10):791-4.
1998: G V Doern; Michael A Pfaller; KC Kugler; J Freeman; Ronald Jones
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(4):764-70.
1998: G V Doern; AB Brueggemann; Michael Blocker; M Dunne; H P Holley; K S Kehl; J Duval; K Kugler; Shan Putnam; A Rauch; Michael A Pfaller
Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(4):757-61.
1998: Y S Chen; SA Marshall; Patricia L Winokur; Stacy Coffman; Werner W Wilke; P R Murray; C A Spiegel; Michael A Pfaller; G V Doern; Ronald Jones
Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.
Journal of clinical microbiology 1998;36(10):2996-3001.
1998: CJ Jessup; Michael A Pfaller; Shawn A Messer; J Zhang; M Tumberland; EK Mbidde; Mahmoud A Ghannoum
Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.
Journal of clinical microbiology 1998;36(10):2874-6.
1998: F Marco; Michael A Pfaller; Shawn A Messer; Ronald Jones
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Diagnostic microbiology and infectious disease 1998;32(1):33-7.
1998: C Wendt; Shawn A Messer; Richard J Hollis; Michael A Pfaller; Loreen A Herwaldt
Epidemiology of polyclonal gram-negative bacteremia.
Diagnostic microbiology and infectious disease 1998;32(1):9-13.
1998: Michael A Pfaller; Sevtap Arikan; Mario Lozano-Chiu; Y Chen; Stacy Coffman; Shawn A Messer; Robert P Rennie; Crystal Sand; T Heffner; John H Rex; J Wang; N Yamane
Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing.
Journal of clinical microbiology 1998;36(9):2609-12.
1998: Michael A Pfaller; Shawn A Messer; A Karlsson; A Bolmström
Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.
Journal of clinical microbiology 1998;36(9):2586-9.
1998: Michael A Pfaller; Shawn A Messer; Richard J Hollis; Ana Espinel-Ingroff; Mahmoud A Ghannoum; H Plavan; Scott B Killian; C C Knapp
Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel.
Diagnostic microbiology and infectious disease 1998;31(4):543-7.
1998: Michael A Pfaller; Ronald Jones; G V Doern; KC Kugler
Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).
Antimicrobial agents and chemotherapy 1998;42(7):1762-70.
1998: Michael A Pfaller; Ronald Jones; G V Doern; Helio S Sader; Richard J Hollis; Shawn A Messer
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
Journal of clinical microbiology 1998;36(7):1886-9.
1998: Ronald Jones; Michael A Pfaller
Bacterial resistance: a worldwide problem.
Diagnostic microbiology and infectious disease 1998;31(2):379-88.
1998: Michael E Klepser; Erika J Ernst; Michael E Ernst; Shawn A Messer; Michael A Pfaller
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
Antimicrobial agents and chemotherapy 1998;42(6):1387-91.
1998: Russell Lewis; Brian C Lund; Michael E Klepser; Erika J Ernst; Michael A Pfaller
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.
Antimicrobial agents and chemotherapy 1998;42(6):1382-6.
1998: Michael A Pfaller; Shawn R Lockhart; Claude Pujol; J A Swails-Wenger; Shawn A Messer; Michael B Edmond; Ronald Jones; Richard P Wenzel; David Soll
Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates.
Journal of clinical microbiology 1998;36(6):1518-29.
1998: Russell Lewis; Michael E Klepser; Michael A Pfaller
Update on clinical antifungal susceptibility testing for Candida species.
Pharmacotherapy 1998;18(3):509-15.
1998: Sandra L Fowler; B Rhoton; S C Springer; S A Messer; Richard J Hollis; Michael A Pfaller
Evidence for person-to-person transmission of Candida lusitaniae in a neonatal intensive-care unit.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1998;19(5):343-5.
1998: Michael A Pfaller; Ronald Jones; Shawn A Messer; Michael B Edmond; Richard P Wenzel
National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.
Diagnostic microbiology and infectious disease 1998;31(1):327-32.
1998: Michael A Pfaller; Shawn A Messer; AK Houston; MS Rangel-Frausto; T Wiblin; Henry M Blumberg; John Edwards; William R Jarvis; Michael Martin; H C Neu; Lisa Saiman; Jan Patterson; J C Dibb; C M Roldan; Michael G Rinaldi; Richard P Wenzel
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species.
Diagnostic microbiology and infectious disease 1998;31(1):289-96.
1998: Michael E Klepser; Erika J Ernst; Russell Lewis; Michael E Ernst; Michael A Pfaller
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.
Antimicrobial agents and chemotherapy 1998;42(5):1207-12.
1998: Michael A Pfaller; F Marco; Shawn A Messer; Ronald Jones
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
Diagnostic microbiology and infectious disease 1998;30(4):251-5.
1998: Michael E Klepser; EJ Wolfe; Michael A Pfaller
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
The Journal of antimicrobial chemotherapy 1998;41(3):397-401.
1998: Ronald Jones; Michael A Pfaller; G V Doern; ME Erwin; Richard J Hollis
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Diagnostic microbiology and infectious disease 1998;30(3):215-28.
1998: SA Marshall; Werner W Wilke; Michael A Pfaller; Ronald Jones
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.
Diagnostic microbiology and infectious disease 1998;30(3):205-14.
1998: Kimberly Ephgrave; R Kleiman-Wexler; Michael A Pfaller; B M Booth; D Reed; L Werkmeister; S Young
Effects of sucralfate vs antacids on gastric pathogens: results of a double-blind clinical trial.
Archives of surgery (Chicago, Ill. : 1960) 1998;133(3):251-7.
1998: Michael A Pfaller; Ronald Jones; Shawn A Messer; Michael B Edmond; Richard P Wenzel
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.
Diagnostic microbiology and infectious disease 1998;30(2):121-9.
1998: G V Doern; Ronald Jones; Michael A Pfaller; ME Erwin; C Ramirez-Rhonda
Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1998;30(2):113-9.
1998: Frank C Odds; Frans Van Gerven; Ana Espinel-Ingroff; M S Bartlett; Mahmoud A Ghannoum; MV Lancaster; Michael A Pfaller; John H Rex; Michael G Rinaldi; THOMAS WALSH
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.
Antimicrobial agents and chemotherapy 1998;42(2):282-8.
1998: F Marco; Michael A Pfaller; Shawn A Messer; Ronald Jones
In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi.
Mycopathologia 1998;141(2):73-7.
1998: SA Marshall; Werner W Wilke; Y S Chen; Michael A Pfaller; Ronald Jones
In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample.
Diagnostic microbiology and infectious disease 1998;30(1):65-9.
1998: Michael A Pfaller; Ronald Jones; G V Doern
Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1998;30(1):45-52.
1998: F Marco; Michael A Pfaller; Shawn Messer; Ronald Jones
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Antimicrobial agents and chemotherapy 1998;42(1):161-3.
1997: Michael A Pfaller; SA Marshall; Ronald Jones
In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.
Diagnostic microbiology and infectious disease 1997;29(4):273-6.
1997: Ronald Jones; Juan C Salazar; Michael A Pfaller; G V Doern
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1997;29(4):265-72.
1997: Michael A Pfaller; Ronald Jones; SA Marshall; Michael B Edmond; Richard P Wenzel
Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.
Diagnostic microbiology and infectious disease 1997;29(4):259-63.
1997: Michael E Klepser; Erika J Ernst; Michael E Ernst; Michael A Pfaller
Growth medium effect on the antifungal activity of LY 303366.
Diagnostic microbiology and infectious disease 1997;29(4):227-31.
1997: Shawn R Lockhart; Sophie Joly; Claude Pujol; Jack D Sobel; Michael A Pfaller; David Soll
Development and verification of fingerprinting probes for Candida glabrata.
Microbiology (Reading, England) 1997;143 ( Pt 12)():3733-46.
1997: Michael A Pfaller; Ronald Jones
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Diagnostic microbiology and infectious disease 1997;29(3):199-201.
1997: Ronald Jones; Michael A Pfaller; SA Marshall; Richard J Hollis; Werner W Wilke
Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
Diagnostic microbiology and infectious disease 1997;29(3):187-92.
1997: Daniel J Diekema; Shawn A Messer; Richard J Hollis; Richard P Wenzel; Michael A Pfaller
An outbreak of Candida parapsilosis prosthetic valve endocarditis.
Diagnostic microbiology and infectious disease 1997;29(3):147-53.
1997: Daniel J Diekema; J Barr; Linda Boyken; BJ Buschelman; Ronald Jones; Michael A Pfaller; Loreen A Herwaldt
A cluster of serious Escherichia coli infections in a neonatal intensive-care unit.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1997;18(11):774-6.
1997: Ronald Jones; SA Marshall; Michael A Pfaller; Werner W Wilke; Richard J Hollis; ME Erwin; Michael B Edmond; Richard P Wenzel
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.
Diagnostic microbiology and infectious disease 1997;29(2):95-102.
1997: Michael A Pfaller; Loreen A Herwaldt
The clinical microbiology laboratory and infection control: emerging pathogens, antimicrobial resistance, and new technology.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(4):858-70.
1997: Werner W Wilke; SA Marshall; Stacy Coffman; Michael A Pfaller; M B Edmund; Richard P Wenzel; Ronald Jones
Vancomycin-resistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program.
Diagnostic microbiology and infectious disease 1997;29(1):43-9.
1997: Michael E Klepser; E J Ernst; Michael A Pfaller
Update on antifungal resistance.
Trends in microbiology 1997;5(9):372-5.
1997: Michael A Pfaller; Ronald Jones; SA Marshall; Stacy Coffman; Richard J Hollis; Michael B Edmond; Richard P Wenzel
Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
Diagnostic microbiology and infectious disease 1997;28(4):211-9.
1997: Michael A Pfaller; Ronald Jones
A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
Diagnostic microbiology and infectious disease 1997;28(4):157-63.
1997: John Edwards; Gerald P Bodey; R A Bowden; T Büchner; Ben E de Pauw; Scott Filler; M A Ghannoum; M Glauser; Raoul Herbrecht; Carol A Kauffman; S Kohno; P Martino; F Meunier; T Mori; Michael A Pfaller; J H Rex; T R Rogers; Robert Rubin; J Solomkin; Claudio Viscoli; THOMAS WALSH; M White
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(1):43-59.
1997: Spencer Redding; Michael A Pfaller; S A Messer; J A Smith; J Prows; L L Bradley; Annette W Fothergill; Michael G Rinaldi
Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.
Journal of clinical microbiology 1997;35(7):1761-5.
1997: L R Putnam; W J Howard; Michael A Pfaller; FP Koontz; Ronald Jones
Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of "direct" inoculation from Bactec 9240 blood culture bottles.
Diagnostic microbiology and infectious disease 1997;28(2):101-4.
1997: M J Bale; C Yang; Michael A Pfaller
Evaluation of growth characteristics on blood agar and eosin methylene blue agar for the identification of Candida (Torulopsis) glabrata.
Diagnostic microbiology and infectious disease 1997;28(2):65-7.
1997: S Weber; Michael A Pfaller; Loreen A Herwaldt
Role of molecular epidemiology in infection control.
Infectious disease clinics of North America 1997;11(2):257-78.
1997: Michael E Klepser; EJ Wolfe; Ronald Jones; C H Nightingale; Michael A Pfaller
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.
Antimicrobial agents and chemotherapy 1997;41(6):1392-5.
1997: T C White; Michael A Pfaller; M G Rinaldi; J Smith; Spencer Redding
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.
Oral diseases 1997;3 Suppl 1():S102-9.
1997: Michael A Pfaller; John H Rex; Michael G Rinaldi
Antifungal susceptibility testing: technical advances and potential clinical applications.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(5):776-84.
1997: Michael A Pfaller; Ronald Jones
In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci.
Diagnostic microbiology and infectious disease 1997;27(4):151-4.
1997: Michael A Pfaller; Shawn A Messer; Stacy Coffman
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
Antimicrobial agents and chemotherapy 1997;41(4):763-6.
1997: Ronald Jones; M R Jacobs; J A Washington; Michael A Pfaller
A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States.
Diagnostic microbiology and infectious disease 1997;27(3):75-83.
1997: J Zhang; Richard J Hollis; Michael A Pfaller
Variations in DNA subtype and antifungal susceptibility among clinical isolates of Candida tropicalis.
Diagnostic microbiology and infectious disease 1997;27(3):63-7.
1997: John H Rex; Michael A Pfaller; John N Galgiani; M S Bartlett; Ana Espinel-Ingroff; Mahmoud A Ghannoum; MV Lancaster; Frank C Odds; Michael G Rinaldi; THOMAS WALSH; Arthur L Barry
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(2):235-47.
1997: Michael A Pfaller; Shawn Messer; Ronald Jones
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
Antimicrobial agents and chemotherapy 1997;41(2):233-5.
1997: Mario Lozano-Chiu; PW Nelson; MV Lancaster; Michael A Pfaller; John H Rex
Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B.
Journal of clinical microbiology 1997;35(1):270-2.
1997: Ana Espinel-Ingroff; M Bartlett; R Bowden; Nai Xun Chin; C Cooper; AW Fothergill; Michael R McGinnis; P Menezes; Shawn A Messer; PW Nelson; Frank C Odds; Lester Pasarell; J Peter; Michael A Pfaller; John H Rex; Michael G Rinaldi; Gillian Shankland; THOMAS WALSH; I Weitzman
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.
Journal of clinical microbiology 1997;35(1):139-43.
1996: Mark W Garrison; D E Anderson; D M Campbell; Karen C Carroll; C L Malone; J D Anderson; Richard J Hollis; Michael A Pfaller
Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model.
Antimicrobial agents and chemotherapy 1996;40(12):2859-64.
1996: P A Meier; C D Carter; S E Wallace; Richard J Hollis; Michael A Pfaller; Loreen A Herwaldt
A prolonged outbreak of methicillin-resistant Staphylococcus aureus in the burn unit of a tertiary medical center.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1996;17(12):798-802.
1996: L Zerva; Richard J Hollis; Michael A Pfaller
In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates.
Journal of clinical microbiology 1996;34(12):3031-4.
1996: Michael E Ernst; Michael E Klepser; E J Wolfe; Michael A Pfaller
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.
Diagnostic microbiology and infectious disease 1996;26(3-4):125-31.
1996: H Swanson; P A Hughes; S A Messer; M L Lepow; Michael A Pfaller
Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant.
The Journal of pediatrics 1996;129(5):688-94.
1996: Christopher J Papasian; J Kinney; Stacy Coffman; Richard J Hollis; Michael A Pfaller
Transmission of Citrobacter koseri from mother to infant documented by ribotyping and pulsed-field gel electrophoresis.
Diagnostic microbiology and infectious disease 1996;26(2):63-7.
1996: M G Cormican; Michael A Pfaller
Standardization of antifungal susceptibility testing.
The Journal of antimicrobial chemotherapy 1996;38(4):561-78.
1996: Elias J Anaissie; Victor L Paetznick; L G Ensign; Ana Espinel-Ingroff; John N Galgiani; C A Hitchcock; M LaRocco; Thomas Patterson; Michael A Pfaller; John H Rex; M G Rinaldi
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.
Antimicrobial agents and chemotherapy 1996;40(10):2387-91.
1996: Mary E Brandt; Michael A Pfaller; Rana A Hajjeh; Edward Graviss; Judy Rees; E D Spitzer; Robert W Pinner; Leonard W Mayer
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group.
The Journal of infectious diseases 1996;174(4):812-20.
1996: Helio S Sader; C F Mendes; A C C Pignatari; Michael A Pfaller
Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(3):631-4.
1996: Michael A Pfaller; M G Cormican
Role of the microbiology laboratory in monitoring and identifying resistance: use of molecular biology.
New horizons (Baltimore, Md.) 1996;4(3):361-9.
1996: M G Cormican; Werner W Wilke; MS Barrett; Michael A Pfaller; Ronald Jones
Phenotypic detection of mec A-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests.
Diagnostic microbiology and infectious disease 1996;25(3):107-12.
1996: Y F Berrouane; Richard J Hollis; Michael A Pfaller
Strain variation among and antifungal susceptibilities of isolates of Candida krusei.
Journal of clinical microbiology 1996;34(7):1856-8.
1996: Michael A Pfaller; S A Messer; A Bolmström; F C Odds; John H Rex
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.
Journal of clinical microbiology 1996;34(7):1691-3.
1996: M G Cormican; Richard J Hollis; Michael A Pfaller
DNA macrorestriction profiles and antifungal susceptibility of Candida (Torulopsis) glabrata.
Diagnostic microbiology and infectious disease 1996;25(2):83-7.
1996: S A Messer; Michael A Pfaller
Clinical evaluation of a dried commercially-prepared microdilution panel for antifungal susceptibility testing.
Diagnostic microbiology and infectious disease 1996;25(2):77-81.
1996: Michael A Pfaller; Christine H Wendt; Richard J Hollis; Richard P Wenzel; S J Fritschel; J J Neubauer; Loreen A Herwaldt
Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent gram-negative bacteremia.
Diagnostic microbiology and infectious disease 1996;25(1):1-8.
1996: H Sanati; S A Messer; Michael A Pfaller; M Witt; R Larsen; Ana Espinel-Ingroff; M Ghannoum
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole.
Journal of clinical microbiology 1996;34(5):1280-2.
1996: L A Waggoner-Fountain; M W Walker; Richard J Hollis; Michael A Pfaller; J E Ferguson; Richard P Wenzel; Leigh Grossman Donowitz
Vertical and horizontal transmission of unique Candida species to premature newborns.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(5):803-8.
1996: Michael A Pfaller
Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22 Suppl 2():S89-94.
1996: Ana Espinel-Ingroff; Michael A Pfaller; M E Erwin; Ronald Jones
Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.
Journal of clinical microbiology 1996;34(4):848-52.
1996: John H Rex; Michael A Pfaller; MV Lancaster; F C Odds; A Bolmström; M G Rinaldi
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole.
Journal of clinical microbiology 1996;34(4):816-7.
1996: W J Howard; B J Buschelman; M J Bale; Michael A Pfaller; FP Koontz; Ronald Jones
Vitek GPS card susceptibility testing accuracy using direct inoculation from BACTEC 9240 blood culture bottles.
Diagnostic microbiology and infectious disease 1996;24(2):109-12.
1996: L J Strausbaugh; D L Sewell; R C Tjoelker; T Heitzman; T Webster; T T Ward; Michael A Pfaller
Comparison of three methods for recovery of yeasts from hands of health-care workers.
Journal of clinical microbiology 1996;34(2):471-3.
1996: P Valenstein; Michael A Pfaller; M Yungbluth
The use and abuse of routine stool microbiology: a College of American Pathologists Q-probes study of 601 institutions.
Archives of pathology & laboratory medicine 1996;120(2):206-11.
1996: Loreen A Herwaldt; M Geiss; Chinghai Kao; Michael A Pfaller
The positive predictive value of isolating coagulase-negative staphylococci from blood cultures.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(1):14-20.
1996: Michael A Pfaller; AK Houston; S Coffmann
Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata.
Journal of clinical microbiology 1996;34(1):58-61.
1995: Michael A Pfaller; J Rhine-Chalberg; A L Barry; John H Rex
Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(6):1507-9.
1995: Francesco Barchiesi; Richard J Hollis; S A Messer; G Scalise; Michael G Rinaldi; Michael A Pfaller
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
Diagnostic microbiology and infectious disease 1995;23(3):99-103.
1995: M G Cormican; Michael A Pfaller
Epidemiology of candidiasis.
Comprehensive therapy 1995;21(11):653-7.
1995: Jana M Swenson; N C Clark; D F Sahm; M J Ferraro; G Doern; J Hindler; James Jorgensen; Michael A Pfaller; L B Reller; M P Weinstein
Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci.
Journal of clinical microbiology 1995;33(11):3019-21.
1995: Helio S Sader; Ronald Jones; Michael A Pfaller
Relapse of catheter-related Flavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(4):997-1000.
1995: Francesco Barchiesi; Richard J Hollis; Maurizio Del Poeta; D A McGough; Giorgio Scalise; Michael G Rinaldi; Michael A Pfaller
Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(3):561-4.
1995: Theresa A Schlager; T S Whittam; J Owen Hendley; Richard J Hollis; Michael A Pfaller; R A Wilson; A Stapleton
Comparison of expression of virulence factors by Escherichia coli causing cystitis and E. coli colonizing the periurethra of healthy girls.
The Journal of infectious diseases 1995;172(3):772-7.
1995: Richard J Hollis; J L Barr; Bradley Doebbeling; Michael A Pfaller; Richard P Wenzel
Familial carriage of methicillin-resistant Staphylococcus aureus and subsequent infection in a premature neonate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(2):328-32.
1995: A I Hartstein; M A Denny; V H Morthland; Ann M LeMonte; Michael A Pfaller
Control of methicillin-resistant Staphylococcus aureus in a hospital and an intensive care unit.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1995;16(7):405-11.
1995: D Sewell; Arthur L Barry; S Allen; P Fuchs; J McLaughlin; Michael A Pfaller
Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.
Antimicrobial agents and chemotherapy 1995;39(7):1591-5.
1995: S Lam; Carol Singer; V Tucci; V H Morthland; Michael A Pfaller; H D Isenberg
The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study.
American journal of infection control 1995;23(3):170-80.
1995: Helio S Sader; Richard J Hollis; Michael A Pfaller
The use of molecular techniques in the epidemiology and control of infectious diseases.
Clinics in laboratory medicine 1995;15(2):407-31.
1995: D King; J Rhine-Chalberg; Michael A Pfaller; S A Moser; William G Merz
Comparison of four DNA-based methods for strain delineation of Candida lusitaniae.
Journal of clinical microbiology 1995;33(6):1467-70.
1995: Michael A Pfaller
Epidemiology of candidiasis.
The Journal of hospital infection 1995;30 Suppl():329-38.
1995: Michael A Pfaller
Epidemiology of fungal infections: the promise of molecular typing.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20(6):1535-9.
1995: Michael A Pfaller
Epidemiology of fungal infections: current perspectives and future directions. Introduction.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20(6):1525.
1995: Michael B Edmond; J F Ober; D L Weinbaum; Michael A Pfaller; T Hwang; M D Sanford; Richard P Wenzel
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20(5):1126-33.
1995: Michael A Pfaller; M Bale; B Buschelman; M Lancaster; Ana Espinel-Ingroff; John H Rex; Michael G Rinaldi; C R Cooper; M R McGinnis
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.
Journal of clinical microbiology 1995;33(5):1104-7.
1995: Michael A Pfaller; S A Messer; S Coffmann
Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.
Journal of clinical microbiology 1995;33(5):1094-7.
1995: D R Reagan; Michael A Pfaller; Richard J Hollis; Richard P Wenzel
Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit.
Diagnostic microbiology and infectious disease 1995;21(4):191-4.
1995: Francesco Barchiesi; Richard J Hollis; D A McGough; Giorgio Scalise; Michael G Rinaldi; Michael A Pfaller
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20(3):634-40.
1995: Andreas Voss; Michael A Pfaller; Richard J Hollis; J Rhine-Chalberg; Bradley Doebbeling
Investigation of Candida albicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods.
Journal of clinical microbiology 1995;33(3):576-80.
1995: Ana Espinel-Ingroff; K Dawson; Michael A Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; Victor L Paetznick; J Peter; M Rinaldi
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.
Antimicrobial agents and chemotherapy 1995;39(2):314-9.
1995: Michael A Pfaller; S A Messer; Richard J Hollis
Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis.
Diagnostic microbiology and infectious disease 1995;21(1):9-14.
1995: John H Rex; Michael A Pfaller; A L Barry; PW Nelson; C D Webb
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.
Antimicrobial agents and chemotherapy 1995;39(1):40-4.
1995: John H Rex; M G Rinaldi; Michael A Pfaller
Resistance of Candida species to fluconazole.
Antimicrobial agents and chemotherapy 1995;39(1):1-8.
1995: Michael A Pfaller; A L Barry
In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
Mycopathologia 1995;130(1):3-9.
1994: A L Barry; S D Allen; P C Fuchs; James Jorgensen; Michael A Pfaller
Revision of quality control limits for broth microdilution tests of fleroxacin and gentamicin with Pseudomonas aeruginosa ATCC 27853.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1994;13(12):1087-9.
1994: Helio S Sader; Michael A Pfaller; Ronald Jones
Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Diagnostic microbiology and infectious disease 1994;20(4):203-8.
1994: Michael A Pfaller; S A Messer; Richard J Hollis
Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.
Diagnostic microbiology and infectious disease 1994;20(3):127-33.
1994: Helio S Sader; Michael A Pfaller; Fred C Tenover; Richard J Hollis; Ronald Jones
Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers.
Journal of clinical microbiology 1994;32(11):2840-2.
1994: Arthur L Barry; Michael A Pfaller; Peter C Fuchs; R R Packer
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
Antimicrobial agents and chemotherapy 1994;38(10):2419-25.
1994: C Ferra; Bradley Doebbeling; Richard J Hollis; Michael A Pfaller; C K Lee; R D Gingrich
Candida tropicalis vertebral osteomyelitis: a late sequela of fungemia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;19(4):697-703.
1994: William E Keene; J M McAnulty; F C Hoesly; L P Williams; Katrina Hedberg; G L Oxman; T J Barrett; Michael A Pfaller; David W Fleming
A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7 and Shigella sonnei.
The New England journal of medicine 1994;331(9):579-84.
1994: L J Strausbaugh; D L Sewell; T T Ward; Michael A Pfaller; T Heitzman; R Tjoelker
High frequency of yeast carriage on hands of hospital personnel.
Journal of clinical microbiology 1994;32(9):2299-300.
1994: David Birnbaum; Loreen A Herwaldt; Donald E Low; M Noble; Michael A Pfaller; R Sherertz; Anthony W Chow
Efficacy of microbial identification system for epidemiologic typing of coagulase-negative staphylococci.
Journal of clinical microbiology 1994;32(9):2113-9.
1994: D L Sewell; Michael A Pfaller; A L Barry
Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole.
Journal of clinical microbiology 1994;32(9):2099-102.
1994: Michael A Pfaller; A L Barry
Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates.
Journal of clinical microbiology 1994;32(8):1992-6.
1994: Michael A Pfaller
Epidemiology and control of fungal infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;19 Suppl 1():S8-13.
1994: M Sabria-Leal; Michael A Pfaller; V H Morthland; S A Young; Richard J Hollis; L Werkmeister; R L Kleiman-Wexler; Kimberly Ephgrave
Molecular epidemiology of gastric colonization by Enterococcus faecalis in a surgical intensive care unit.
Diagnostic microbiology and infectious disease 1994;19(4):197-202.
1994: Bradley Doebbeling; D R Reagan; Michael A Pfaller; A K Houston; Richard J Hollis; Richard P Wenzel
Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage.
Archives of internal medicine 1994;154(13):1505-8.
1994: Jana M Swenson; N C Clark; M J Ferraro; D F Sahm; G Doern; Michael A Pfaller; L B Reller; M P Weinstein; R J Zabransky; Fred C Tenover
Development of a standardized screening method for detection of vancomycin-resistant enterococci.
Journal of clinical microbiology 1994;32(7):1700-4.
1994: Michael A Pfaller; M Bale; B Buschelman; M Lancaster; Ana Espinel-Ingroff; John H Rex; Michael G Rinaldi
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.
Journal of clinical microbiology 1994;32(7):1650-3.
1994: Michael A Pfaller; Q Vu; M Lancaster; Ana Espinel-Ingroff; A Fothergill; C Grant; Michael R McGinnis; Lester Pasarell; Michael G Rinaldi; L Steele-Moore
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates.
Journal of clinical microbiology 1994;32(7):1625-8.
1994: P C Fuchs; A L Barry; Michael A Pfaller
Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria.
The Journal of antimicrobial chemotherapy 1994;33(6):1147-54.
1994: M Sabria-Leal; V H Morthland; Maria Luisa Pedro-Botet; Nieves Sopena; M Gimenez-Perez; M L Branchini; Michael A Pfaller
Molecular epidemiology for local outbreaks of methicillin resistant Staphylococcus aureus (MRSA). The need for several methods.
European journal of epidemiology 1994;10(3):325-30.
1994: Michael A Pfaller; M J Bale; B Buschelman; Paul R Rhomberg
Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata.
Diagnostic microbiology and infectious disease 1994;19(2):75-80.
1994: Michael A Pfaller; B Buschelman; M J Bale; M Lancaster; Ana Espinel-Ingroff; John H Rex; Michael G Rinaldi
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates.
Diagnostic microbiology and infectious disease 1994;19(1):9-13.
1994: Andreas Voss; Richard J Hollis; Michael A Pfaller; Richard P Wenzel; Bradley Doebbeling
Investigation of the sequence of colonization and candidemia in nonneutropenic patients.
Journal of clinical microbiology 1994;32(4):975-80.
1994: Trish M Perl; Paul R Rhomberg; M J Bale; P C Fuchs; Ronald Jones; FP Koontz; Michael A Pfaller
Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species.
Diagnostic microbiology and infectious disease 1994;18(3):151-5.
1994: Michael A Pfaller
Application of new technology to the detection, identification, and antimicrobial susceptibility testing of mycobacteria.
American journal of clinical pathology 1994;101(3):329-37.
1994: J C McLaughlin; Arthur L Barry; Peter C Fuchs; E H Gerlach; D J Hardy; Michael A Pfaller
In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1994;33(2):223-30.
1994: Spencer Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; Michael A Pfaller
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;18(2):240-2.
1994: Michael A Pfaller; C Grant; V Morthland; J Rhine-Chalberg
Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.
Journal of clinical microbiology 1994;32(2):506-9.
1994: M L Branchini; Michael A Pfaller; J Rhine-Chalberg; T Frempong; H D Isenberg
Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis.
Journal of clinical microbiology 1994;32(2):452-6.
1994: A L Barry; S D Allen; P C Fuchs; James Jorgensen; Michael A Pfaller
Quality control parameters for broth microdilution susceptibility testing of amoxicillin and amoxicillin-clavulanic acid.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1994;13(2):186-8.
1994: C E Grant; D L Sewell; Michael A Pfaller; R V Bumgardner; J A Williams
Evaluation of two commercial systems for identification of coagulase-negative staphylococci to species level.
Diagnostic microbiology and infectious disease 1994;18(1):1-5.
1994: Michael A Pfaller; J Rhine-Chalberg; Spencer Redding; J Smith; G Farinacci; A W Fothergill; Michael G Rinaldi
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis.
Journal of clinical microbiology 1994;32(1):59-64.
1994: J Van Cutsem; H Kurata; H Matsuoka; Y Mikami; Michael A Pfaller; G M Scalarone; M G Rinaldi
Antifungal drug susceptibility testing.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1994;32 Suppl 1():267-76.
1993: Michael A Pfaller; A L Barry; L D Sabath; B N Kreiswirth; P R Murray; P C Fuchs; J C McLaughlin
In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers.
European journal of epidemiology 1993;9(6):658-62.
1993: M L Branchini; V H Morthland; A T Tresoldi; A Von Nowakonsky; M B Dias; Michael A Pfaller
Application of genomic DNA subtyping by pulsed field gel electrophoresis and restriction enzyme analysis of plasmid DNA to characterize methicillin-resistant Staphylococcus aureus from two nosocomial outbreaks.
Diagnostic microbiology and infectious disease 1993;17(4):275-81.
1993: J H Rex; Michael A Pfaller; M G Rinaldi; A Polak; John N Galgiani
Antifungal susceptibility testing.
Clinical microbiology reviews 1993;6(4):367-81.
1993: D L Sewell; A L Rashad; W J Rourke; Sharon Lee Poor; J A McCarthy; Michael A Pfaller
Comparison of the Septi-Chek AFB and BACTEC systems and conventional culture for recovery of mycobacteria.
Journal of clinical microbiology 1993;31(10):2689-91.
1993: Kimberly Ephgrave; R Kleiman-Wexler; Michael A Pfaller; B Booth; L Werkmeister; S Young
Postoperative pneumonia: a prospective study of risk factors and morbidity.
Surgery 1993;114(4):815-9; discussion 819-21.
1993: N A Back; C C Linnemann; Michael A Pfaller; J L Staneck; V Morthland
Recurrent epidemics caused by a single strain of erythromycin-resistant Staphylococcus aureus. The importance of molecular epidemiology.
JAMA : the journal of the American Medical Association 1993;270(11):1329-33.
1993: Bradley Doebbeling; Debra L Breneman; H C Neu; R Aly; B G Yangco; H P Holley; R J Marsh; Michael A Pfaller; J E McGowan; B E Scully
Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;17(3):466-74.
1993: Peter C Fuchs; Arthur L Barry; Michael A Pfaller
Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
Journal of clinical microbiology 1993;31(8):2236-7.
1993: Peter C Fuchs; Arthur L Barry; Michael A Pfaller; D J Hardy; J C McLaughlin; E H Gerlach
In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.
Diagnostic microbiology and infectious disease 1993;17(2):171-5.
1993: Arthur L Barry; Michael A Pfaller; Peter C Fuchs
Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(7):548-53.
1993: Michael A Pfaller; Arthur L Barry; Peter C Fuchs
Evaluation of disk susceptibility testing of fosfomycin tromethamine.
Diagnostic microbiology and infectious disease 1993;17(1):67-70.
1993: Arthur L Barry; Michael A Pfaller; Peter C Fuchs
Ramoplanin susceptibility testing criteria.
Journal of clinical microbiology 1993;31(7):1932-5.
1993: Michael A Pfaller; A L Barry; P C Fuchs
Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.
Journal of clinical microbiology 1993;31(7):1924-6.
1993: Arthur L Barry; Michael A Pfaller; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Ampicillin-sulbactam susceptibility testing criteria.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(6):469-72.
1993: Michael A Pfaller; Michael G Rinaldi
Antifungal susceptibility testing. Current state of technology, limitations, and standardization.
Infectious disease clinics of North America 1993;7(2):435-44.
1993: Michael A Pfaller; Arthur L Barry; Peter C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(5):356-62.
1993: Arthur L Barry; Michael A Pfaller; Peter C Fuchs; Fred C Tenover; L B Reller; S D Allen; D J Hardy; E H Gerlach
Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(5):352-6.
1993: A L Barry; Michael A Pfaller; P C Fuchs
The antibacterial activity of co-amoxiclav.
The Journal of antimicrobial chemotherapy 1993;31(4):612-5.
1993: Michael A Pfaller; A L Barry; P C Fuchs
Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399.
Antimicrobial agents and chemotherapy 1993;37(4):893-5.
1993: Arthur L Barry; Michael A Pfaller; Peter C Fuchs
Dirithromycin disc susceptibility tests: interpretative criteria and quality control parameters.
The Journal of antimicrobial chemotherapy 1993;31 Suppl C():27-37.
1993: Michael A Pfaller; Arthur L Barry; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(3):200-5.
1993: Bradley Doebbeling; Paul F Lehmann; Richard J Hollis; L C Wu; A F Widmer; Andreas Voss; Michael A Pfaller
Comparison of pulsed-field gel electrophoresis with isoenzyme profiles as a typing system for Candida tropicalis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(3):377-83.
1993: W W Hoover; E H Gerlach; D J Hoban; George Miltiades Eliopoulos; Michael A Pfaller; Ronald Jones
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.
Diagnostic microbiology and infectious disease 1993;16(2):111-8.
1993: Michael A Pfaller; Arthur L Barry; Peter C Fuchs
RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria.
The Journal of antimicrobial chemotherapy 1993;31(1):81-8.
1993: R A Fromtling; John N Galgiani; Michael A Pfaller; Ana Espinel-Ingroff; Ken Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.
Antimicrobial agents and chemotherapy 1993;37(1):39-45.
1993: Arthur L Barry; Peter C Fuchs; Michael A Pfaller
Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.
Antimicrobial agents and chemotherapy 1993;37(1):14-8.
1993: Michael A Pfaller; I Cabezudo; B Buschelman; M Bale; T Howe; M Vitug; H J Linton; M Densel
Value of the Hybritech ICON Candida Assay in the diagnosis of invasive candidiasis in high-risk patients.
Diagnostic microbiology and infectious disease 1993;16(1):53-60.
1993: Antoni Trilla; Mary D Nettleman; Richard J Hollis; M Fredrickson; Richard P Wenzel; Michael A Pfaller
Restriction endonuclease analysis of plasmid DNA from methicillin-resistant Staphylococcus aureus: clinical application over a three-year period.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1993;14(1):29-35.
1993: J N Rodrigues; J L Amaral; I L Leme; A C C Pignatari; S Wey; Richard J Hollis; Michael A Pfaller; Ronald Jones
Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil.
Diagnostic microbiology and infectious disease 1993;16(1):9-16.
1993: M Bale; M Sanford; Richard J Hollis; Michael A Pfaller
Application of a biotyping system and DNA restriction fragment analysis to the study of Serratia marcescens from hospitalized patients.
Diagnostic microbiology and infectious disease 1993;16(1):1-7.
1992: Ana Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; Ken Bartizal; John N Galgiani; K Villareal; Michael A Pfaller; T Gerarden; M G Rinaldi
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.
Journal of clinical microbiology 1992;30(12):3138-45.
1992: B Nyström; U Ransjö; S Ringertz; G Faxelius; R Tunell; G Ohman; J Wilton; Michael A Pfaller
Colonization with coagulase-negative staphylococci in two neonatal units.
The Journal of hospital infection 1992;22(4):287-98.
1992: Michael A Pfaller
Laboratory aids in the diagnosis of invasive candidiasis.
Mycopathologia 1992;120(2):65-72.
1992: Richard P Wenzel; Mary D Nettleman; Michael A Pfaller
[Methicillin-resistant Staphylococcus aureus].
Enfermedades infecciosas y microbiología clínica 1992;10 Suppl 3():3-6.
1992: Trish M Perl; T H Haugen; Michael A Pfaller; Richard J Hollis; A D Lakeman; R J Whitley; D Nicholson; G A Hunter; Richard P Wenzel
Transmission of herpes simplex virus type 1 infection in an intensive care unit.
Annals of internal medicine 1992;117(7):584-6.
1992: D J Hardy; Arthur L Barry; Peter C Fuchs; E H Gerlach; J C McLaughlin; Michael A Pfaller
Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(10):926-30.
1992: Michael A Pfaller; B Dupont; G S Kobayashi; J Müller; Michael G Rinaldi; Ana Espinel-Ingroff; S Shadomy; P F Troke; THOMAS WALSH; D W Warnock
Standardized susceptibility testing of fluconazole: an international collaborative study.
Antimicrobial agents and chemotherapy 1992;36(9):1805-9.
1992: E H Gerlach; Ronald Jones; S D Allen; F P Koontz; P R Murray; Michael A Pfaller; J A Washington; M E Erwin
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
Diagnostic microbiology and infectious disease 1992;15(6):537-43.
1992: Michael A Pfaller; Arthur L Barry; Peter C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(8):728-32.
1992: Bradley Doebbeling; G L Stanley; C T Sheetz; Michael A Pfaller; A K Houston; L Annis; N Li; Richard P Wenzel
Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units.
The New England journal of medicine 1992;327(2):88-93.
1992: M L Sanchez; Michael A Pfaller; I Cabezudo; M Bale; B Buschelman
Diagnosis of disseminated candidiasis in hospitalized patients using the Cand-Tec latex agglutination assay.
Mycopathologia 1992;118(3):153-62.
1992: C Pannuti; Roger Gingrich; Michael A Pfaller; Chinghai Kao; Richard P Wenzel
Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors.
Cancer 1992;69(11):2653-62.
1992: Douglas S Wakefield; Michael A Pfaller; R L Ludke; Richard P Wenzel
Methods for estimating days of hospitalization due to nosocomial infections.
Medical care 1992;30(4):373-6.
1992: Michael A Pfaller; Richard P Wenzel
Impact of the changing epidemiology of fungal infections in the 1990s.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(4):287-91.
1992: A C C Pignatari; Linda Boyken; Loreen A Herwaldt; Richard J Hollis; I Leme; Ricardo Sesso; Michael A Pfaller
Application of restriction endonuclease analysis of chromosomal DNA in the study of Staphylococcus aureus colonization in continuous ambulatory peritoneal dialysis patients.
Diagnostic microbiology and infectious disease 1992;15(3):195-9.
1992: Michael A Pfaller
Epidemiological typing methods for mycoses.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;14 Suppl 1():S4-10.
1992: G Patrick Kealey; J A Heinle; Robert W Lewis; Michael A Pfaller; M D Rosenquist
Value of the Candida antigen assay in diagnosis of systemic candidiasis in burn patients.
The Journal of trauma 1992;32(3):285-8.
1992: Robert J Sherertz; K S Gledhill; K D Hampton; Michael A Pfaller; Laurence B Givner; Jon S Abramson; R G Dillard
Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit.
The Journal of pediatrics 1992;120(3):455-61.
1992: Arthur L Barry; Michael A Pfaller; Peter C Fuchs
Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(3):243-6.
1992: Loreen A Herwaldt; Richard J Hollis; Linda Boyken; Michael A Pfaller
Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1992;13(2):86-92.
1992: Michael A Pfaller; J Riley
Effects of fluconazole on the sterol and carbohydrate composition of four species of Candida.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(2):152-6.
1992: Michael A Pfaller; Ronald Jones; JA Washington; FP Koontz; E H Gerlach; ME Erwin
Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
Diagnostic microbiology and infectious disease 1992;15(2):145-50.
1992: Michael A Pfaller
The use of molecular techniques for epidemiologic typing of Candida species.
Current topics in medical mycology 1992;4():43-63.
1992: Arthur L Barry; Peter C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin; Michael A Pfaller
Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae.
Antimicrobial agents and chemotherapy 1992;36(1):137-43.
1992: Bradley Doebbeling; Michael A Pfaller; Richard J Hollis; Linda Boyken; A C C Pignatari; Loreen A Herwaldt; Richard P Wenzel
Restriction endonuclease analysis of Staphylococcus aureus plasmid DNA from three continents.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(1):4-8.
1992: Glenn D Roberts; Michael A Pfaller; E Gueho; T R Rogers; C De Vroey; William G Merz
Developments in the diagnostic mycology laboratory.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1992;30 Suppl 1():241-8.
1992: John N Galgiani; M G Rinaldi; A M Polak; Michael A Pfaller
Standardization of antifungal susceptibility testing.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1992;30 Suppl 1():213-24.
1991: A L Barry; P C Fuchs; Michael A Pfaller
Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(12):1080-1.
1991: Loreen A Herwaldt; Linda Boyken; Michael A Pfaller
In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(12):1007-12.
1991: Richard P Wenzel; Michael A Pfaller
Infection control: the premier quality assessment program in United States hospitals.
The American journal of medicine 1991;91(3B):27S-31S.
1991: C C Linnemann; P Moore; J L Staneck; Michael A Pfaller
Reemergence of epidemic methicillin-resistant Staphylococcus aureus in a general hospital associated with changing staphylococcal strains.
The American journal of medicine 1991;91(3B):238S-244S.
1991: Mary D Nettleman; Antoni Trilla; M Fredrickson; Michael A Pfaller
Assigning responsibility: using feedback to achieve sustained control of methicillin-resistant Staphylococcus aureus.
The American journal of medicine 1991;91(3B):228S-232S.
1991: Richard P Wenzel; Mary D Nettleman; Ronald Jones; Michael A Pfaller
Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.
The American journal of medicine 1991;91(3B):221S-227S.
1991: Richard P Wenzel; Michael A Pfaller
Candida species: emerging hospital bloodstream pathogens.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1991;12(9):523-4.
1991: P R Murray; S D Allen; M E Erwin; E H Gerlach; Ronald Jones; F P Koontz; Michael A Pfaller; J A Washington
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(9):776-81.
1991: Ronald Jones; E H Gerlach; FP Koontz; P R Murray; Michael A Pfaller; JA Washington; ME Erwin; C C Knapp
Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.
Diagnostic microbiology and infectious disease 1991;14(5):383-8.
1991: D Levenson; Michael A Pfaller; Miriam Smith; Richard J Hollis; T Gerarden; C B Tucci; H D Isenberg
Candida zeylanoides: another opportunistic yeast.
Journal of clinical microbiology 1991;29(8):1689-92.
1991: JA Washington; Ronald Jones; S D Allen; E H Gerlach; F P Koontz; P R Murray; Michael A Pfaller; ME Erwin
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.
Antimicrobial agents and chemotherapy 1991;35(7):1508-11.
1991: Ronald Jones; Michael A Pfaller; S D Allen; E H Gerlach; P C Fuchs; K E Aldridge
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.
Diagnostic microbiology and infectious disease 1991;14(4):361-4.
1991: Michael A Pfaller; D Sahm; C O'Hara; C Ciaglia; M Yu; N Yamane; G Scharnweber; D Rhoden
Comparison of the autoSCAN-W/A rapid bacterial identification system and the Vitek AutoMicrobic system for identification of gram-negative bacilli.
Journal of clinical microbiology 1991;29(7):1422-8.
1991: Richard P Wenzel; Michael A Pfaller
Feasible and desirable future targets for reducing the costs of hospital infections.
The Journal of hospital infection 1991;18 Suppl A():94-8.
1991: Richard P Wenzel; Michael A Pfaller
Handwashing: efficacy versus acceptance. A brief essay.
The Journal of hospital infection 1991;18 Suppl B():65-8.
1991: Bradley Doebbeling; Richard J Hollis; H D Isenberg; Richard P Wenzel; Michael A Pfaller
Restriction fragment analysis of a Candida tropicalis outbreak of sternal wound infections.
Journal of clinical microbiology 1991;29(6):1268-70.
1991: G D Kamal; Michael A Pfaller; L E Rempe; P J Jebson
Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial.
JAMA : the journal of the American Medical Association 1991;265(18):2364-8.
1991: Michael A Pfaller; Douglas S Wakefield; Richard J Hollis; M Fredrickson; E Evans; Robert Michael Massanari
The clinical microbiology laboratory as an aid in infection control. The application of molecular techniques in epidemiologic studies of methicillin-resistant Staphylococcus aureus.
Diagnostic microbiology and infectious disease 1991;14(3):209-17.
1991: THOMAS WALSH; J W Hathorn; Jack D Sobel; William G Merz; V Sanchez; S M Maret; H R Buckley; Michael A Pfaller; Robert L Schaufele; C Sliva
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis.
The New England journal of medicine 1991;324(15):1026-31.
1991: Peter C Fuchs; Arthur L Barry; Michael A Pfaller; S D Allen; E H Gerlach
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Antimicrobial agents and chemotherapy 1991;35(4):764-6.
1991: A C C Pignatari; Ronald Jones; M R Barrett; Ricardo Sesso; I Leme; Michael A Pfaller
Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infection.
Journal of chemotherapy (Florence, Italy) 1991;3(2):108-16.
1991: Ronald Jones; J A Washington; Michael A Pfaller; F P Koontz; E H Gerlach; M E Erwin
Quality control guidelines for Haemophilus test medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246.
The Journal of antimicrobial chemotherapy 1991;27(3):390-2.
1991: Michael A Pfaller
Diagnostic applications of DNA probes.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1991;12(2):103-10.
1991: Ronald Jones; E H Gerlach; FP Koontz; P R Murray; Michael A Pfaller; JA Washington; ME Erwin; C C Knapp
Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan.
Journal of clinical microbiology 1991;29(2):363-6.
1991: D R Reagan; Bradley Doebbeling; Michael A Pfaller; C T Sheetz; A K Houston; Richard J Hollis; Richard P Wenzel
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment.
Annals of internal medicine 1991;114(2):101-6.
1991: M Reznicek; M Bale; Michael A Pfaller
Application of DNA probes to antimicrobial susceptibility testing of Legionella pneumophila.
Diagnostic microbiology and infectious disease 1991;14(1):7-10.
1991: A F Widmer; Michael A Pfaller; Richard P Wenzel
Failure to isolate methicillin-resistant Staphylococcus aureus from stethoscopes in two hospitals with endemic strains.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(1):46.
1991: C S Pannuti; Roger Gingrich; Michael A Pfaller; Richard P Wenzel
Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):77-84.
1990: D R Reagan; Michael A Pfaller; Richard J Hollis; Richard P Wenzel
Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe.
Journal of clinical microbiology 1990;28(12):2733-8.
1990: A L Barry; P C Fuchs; Michael A Pfaller; S D Allen; E H Gerlach
Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(12):906-8.
1990: Michael A Pfaller; I Cabezudo; Richard J Hollis; B Huston; Richard P Wenzel
The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients.
Diagnostic microbiology and infectious disease 1990;13(6):481-9.
1990: Loreen A Herwaldt; Linda Boyken; Michael A Pfaller
Biotyping of coagulase-negative staphylococci. 108 isolates from nosocomial bloodstream infections.
Diagnostic microbiology and infectious disease 1990;13(6):461-6.
1990: Trish M Perl; Michael A Pfaller; AK Houston; Richard P Wenzel
Effect of serum on the in vitro activities of 11 broad-spectrum antibiotics.
Antimicrobial agents and chemotherapy 1990;34(11):2234-9.
1990: Michael A Pfaller; J Riley; T Gerarden
Polyamine depletion and growth inhibition of Cryptococcus neoformans by alpha-difluoromethylornithine and cyclohexylamine.
Mycopathologia 1990;112(1):27-32.
1990: Michael A Pfaller; M G Rinaldi; John N Galgiani; M S Bartlett; B A Body; Ana Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Collaborative investigation of variables in susceptibility testing of yeasts.
Antimicrobial agents and chemotherapy 1990;34(9):1648-54.
1990: L A Veach; Michael A Pfaller; M Barrett; FP Koontz; Richard P Wenzel
Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection.
Journal of clinical microbiology 1990;28(9):2064-8.
1990: A C C Pignatari; Michael A Pfaller; Richard J Hollis; Ricardo Sesso; I Leme; Loreen A Herwaldt
Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.
Journal of clinical microbiology 1990;28(9):1898-902.
1990: I Cabezudo; Michael A Pfaller; M Barrett; M Bale; Richard P Wenzel
In vitro comparison of mezlocillin and piperacillin plus tobramycin or gentamicin versus 100 gram-negative nosocomial bloodstream isolates.
American journal of infection control 1990;18(4):250-6.
1990: Bradley Doebbeling; Michael A Pfaller; K R Kuhns; Robert Michael Massanari; Douglas M Behrendt; Richard P Wenzel
Cardiovascular surgery prophylaxis. A randomized, controlled comparison of cefazolin and cefuroxime.
The Journal of thoracic and cardiovascular surgery 1990;99(6):981-9.
1990: Bradley Doebbeling; Michael A Pfaller; M J Bale; Richard P Wenzel
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(4):298-301.
1990: Michael A Pfaller; J Riley; T Koerner
Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans.
Diagnostic microbiology and infectious disease 1990;13(1):31-5.
1989: Michael A Pfaller; J Riley; T Koerner
Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1989;8(12):1067-70.
1989: R L Minor; Michael A Pfaller; Roger Gingrich; Linda J Burns
Disseminated Fusarium infections in patients following bone marrow transplantation.
Bone marrow transplantation 1989;4(6):653-8.
1989: Michael A Pfaller; T Gerarden
Susceptibility of clinical isolates of Candida spp. to terconazole and other azole antifungal agents.
Diagnostic microbiology and infectious disease 1989;12(6):467-71.
1989: Ronald Jones; Michael A Pfaller; Peter C Fuchs; K Aldridge; S D Allen; E H Gerlach
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
Diagnostic microbiology and infectious disease 1989;12(6):489-94.
1989: S B Wey; Motomi Mori; Michael A Pfaller; Robert F Woolson; Richard P Wenzel
Risk factors for hospital-acquired candidemia. A matched case-control study.
Archives of internal medicine 1989;149(10):2349-53.
1989: G L Stanley; Michael A Pfaller; Motomi Mori; Richard P Wenzel
Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency.
The Journal of hospital infection 1989;14(3):217-25.
1989: I Cabezudo; Michael A Pfaller; T Gerarden; FP Koontz; Richard P Wenzel; Roger Gingrich; K Heckman; C P Burns
Value of the Cand-Tec Candida antigen assay in the diagnosis and therapy of systemic candidiasis in high-risk patients.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1989;8(9):770-7.
1989: M A de Groote; Michael Martin; P Densen; Michael A Pfaller; Richard P Wenzel
Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo.
JAMA : the journal of the American Medical Association 1989;262(2):249-51.
1989: Michael A Pfaller; Richard J Hollis; W Johnson; Robert Michael Massanari; C Helms; Richard P Wenzel; N Hall; N Moyer; J Joly
The application of molecular and immunologic techniques to study the epidemiology of Legionella pneumophila serogroup 1.
Diagnostic microbiology and infectious disease 1989;12(4):295-302.
1989: I Cabezudo; Michael A Pfaller; M Bale; Richard P Wenzel
In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Diagnostic microbiology and infectious disease 1989;12(4):337-41.
1989: Michael Martin; Michael A Pfaller; Robert Michael Massanari; Richard P Wenzel
Use of cellular hydrophobicity, slime production, and species identification markers for the clinical significance of coagulase-negative staphylococcal isolates.
American journal of infection control 1989;17(3):130-5.
1989: Michael A Pfaller
Infection control: opportunistic fungal infections--the increasing importance of Candida species.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1989;10(6):270-3.
1989: Michael A Pfaller; R Gordee; T Gerarden; M Yu; Richard P Wenzel
Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1989;8(6):564-7.
1989: Ronald Jones; K E Aldridge; S D Allen; Arthur L Barry; Peter C Fuchs; E H Gerlach; Michael A Pfaller
Multicenter in vitro evaluation of SM-7338, a new carbapenem.
Antimicrobial agents and chemotherapy 1989;33(4):562-5.
1989: Michael Martin; Michael A Pfaller; P B Rojas; Robert F Woolson; Richard P Wenzel
In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approach.
The Journal of antimicrobial chemotherapy 1989;23(3):353-61.
1989: Michael A Pfaller; M Barrett; FP Koontz; Richard P Wenzel; Mark D Cunningham; N Rollins; R P Darveau
Clinical evaluation of a direct fluorescent monoclonal antibody test for detection of Pseudomonas aeruginosa in blood cultures.
Journal of clinical microbiology 1989;27(3):558-60.
1989: M D Wolf; Michael A Pfaller; Richard J Hollis; T A Weingeist
Staphylococcus aureus conjunctivitis and sepsis in a neutropenic patient.
American journal of ophthalmology 1989;107(1):87-8.
1989: Michael Martin; Michael A Pfaller; Richard P Wenzel
Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay.
Annals of internal medicine 1989;110(1):9-16.
1989: P C Fuchs; Ronald Jones; A L Barry; S D Allen; L W Ayers; Michael A Pfaller
Desacetylcefotaxime--another broad spectrum cephalosporin?
The Journal of antimicrobial chemotherapy 1989;23(1):165-7.
1989: Michael A Pfaller; S Wey; T Gerarden; A Houston; Richard P Wenzel
Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents.
Diagnostic microbiology and infectious disease 1989;12(1):1-4.
1988: S B Wey; Motomi Mori; Michael A Pfaller; Robert F Woolson; Richard P Wenzel
Hospital-acquired candidemia. The attributable mortality and excess length of stay.
Archives of internal medicine 1988;148(12):2642-5.
1988: Arthur L Barry; K E Aldridge; S D Allen; Peter C Fuchs; E H Gerlach; Ronald Jones; Michael A Pfaller
In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(6):794-8.
1988: Bradley Doebbeling; M J Bale; FP Koontz; C M Helms; Richard P Wenzel; Michael A Pfaller
Prospective evaluation of the Gen-Probe assay for detection of legionellae in respiratory specimens.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(6):748-52.
1988: Douglas S Wakefield; C M Helms; Robert Michael Massanari; Motomi Mori; Michael A Pfaller
Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections.
American journal of infection control 1988;16(5):185-92.
1988: Michael A Pfaller; T Preston; M Bale; FP Koontz; B A Body
Comparison of the Quantum II, API Yeast Ident, and AutoMicrobic systems for identification of clinical yeast isolates.
Journal of clinical microbiology 1988;26(10):2054-8.
1988: Robert Michael Massanari; Michael A Pfaller; Douglas S Wakefield; G T Hammons; L A McNutt; Robert F Woolson; C M Helms
Implications of acquired oxacillin resistance in the management and control of Staphylococcus aureus infections.
The Journal of infectious diseases 1988;158(4):702-9.
1988: Michael A Pfaller; T Gerarden; M Yu; Richard P Wenzel
Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019.
Diagnostic microbiology and infectious disease 1988;11(1):1-9.
1988: Bradley Doebbeling; Michael A Pfaller; A K Houston; Richard P Wenzel
Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing.
Annals of internal medicine 1988;109(5):394-8.
1988: Ronald Jones; K E Aldridge; A L Barry; P C Fuchs; E H Gerlach; Michael A Pfaller; J A Washington
Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.
Diagnostic microbiology and infectious disease 1988;10(4):221-40.
1988: David Soll; M Staebell; C Langtimm; Michael A Pfaller; J Hicks; T V Rao
Multiple Candida strains in the course of a single systemic infection.
Journal of clinical microbiology 1988;26(8):1448-59.
1988: Michael A Pfaller; L Burmeister; M S Bartlett; M G Rinaldi
Multicenter evaluation of four methods of yeast inoculum preparation.
Journal of clinical microbiology 1988;26(8):1437-41.
1988: Michael A Pfaller; Loreen A Herwaldt
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci.
Clinical microbiology reviews 1988;1(3):281-99.
1988: Michael Martin; M J Bock; Michael A Pfaller; Richard P Wenzel
Respiratory syncytial virus infections in adult bone marrow transplant recipients.
Lancet 1988;1(8599):1396-7.
1988: B A Body; Michael A Pfaller; J Durrer; FP Koontz; D H Gröschel
Comparison of the lysis centrifugation and radiometric blood culture systems for recovery of yeast.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(3):417-20.
1988: C M Helms; Robert Michael Massanari; Richard P Wenzel; Michael A Pfaller; N P Moyer; N Hall
Legionnaires' disease associated with a hospital water system. A five-year progress report on continuous hyperchlorination.
JAMA : the journal of the American Medical Association 1988;259(16):2423-7.
1988: Michael A Pfaller; J Riley; T Gerarden
Polyamine depletion and growth inhibition in Candida albicans and Candida tropicalis by alpha-difluoromethylornithine and cyclohexylamine.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1988;26(2):119-26.
1988: Michael A Pfaller; D Davenport; M Bale; M Barrett; FP Koontz; Robert Michael Massanari
Development of the quantitative micro-test for slime production by coagulase-negative staphylococci.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1988;7(1):30-3.
1988: Ronald Jones; A L Barry; Michael A Pfaller; S D Allen; L W Ayers; P C Fuchs
Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.
Diagnostic microbiology and infectious disease 1988;9(1):59-63.
1988: Michael A Pfaller; Douglas S Wakefield; B Stewart; M Bale; G T Hammons; Robert Michael Massanari
Evaluation of laboratory methods for the classification of oxacillin-resistant and oxacillin-susceptible Staphylococcus aureus.
American journal of clinical pathology 1988;89(1):120-5.
1987: Michael A Pfaller; I Cabezudo; FP Koontz; M Bale; Roger Gingrich
Predictive value of surveillance cultures for systemic infection due to Candida species.
European journal of clinical microbiology 1987;6(6):628-33.
1987: B Wasilauskas; R Gay; P Zwadyk; Michael A Pfaller; FP Koontz
Multicenter comparison of MicroScan and BACTEC blood culture systems.
Journal of clinical microbiology 1987;25(12):2355-8.
1987: Michael A Pfaller; T Gerarden
The use of the Prompt Inoculation System in preparing a standardized yeast inoculum.
American journal of clinical pathology 1987;88(6):743-5.
1987: Michael A Pfaller; M Bale; M Barrett
In-vitro activity of paldimycin against methicillin-resistant and susceptible isolates of Staphylococcus aureus and S. epidermidis.
The Journal of antimicrobial chemotherapy 1987;20(2):286-8.
1987: Michael A Pfaller; Douglas S Wakefield; G T Hammons; Robert Michael Massanari
Variation from standards in Staphylococcus aureus susceptibility testing.
American journal of clinical pathology 1987;88(2):231-5.
1987: Michael A Pfaller
Strain variation among Candida species: application of various typing methods to study the epidemiology and pathogenesis of candidiasis in hospitalized patients.
Infection control : IC 1987;8(7):273-6.
1987: Douglas S Wakefield; Michael A Pfaller; G T Hammons; Robert Michael Massanari
Use of the appropriateness evaluation protocol for estimating the incremental costs associated with nosocomial infections.
Medical care 1987;25(6):481-8.
1987: Douglas S Wakefield; Michael A Pfaller; Robert Michael Massanari; G T Hammons
Variation in methicillin-resistant Staphylococcus aureus occurrence by geographic location and hospital characteristics.
Infection control : IC 1987;8(4):151-7.
1987: Michael A Pfaller; T Gerarden; J Riley
Growth inhibition of pathogenic yeast isolates by alpha-difluoromethylornithine: an inhibition of ornithine decarboxylase.
Mycopathologia 1987;98(1):3-8.
1987: Michael A Pfaller; B Ringenberg; L Rames; J Hegeman; FP Koontz
The usefulness of screening tests for pyuria in combination with culture in the diagnosis of urinary tract infection.
Diagnostic microbiology and infectious disease 1987;6(3):207-15.
1987: B Slutsky; M Staebell; J Anderson; L Risen; Michael A Pfaller; David Soll
"White-opaque transition": a second high-frequency switching system in Candida albicans.
Journal of bacteriology 1987;169(1):189-97.
1986: Michael A Pfaller; M Bale; T Preston; W Howard; FP Koontz
In vitro inhibitory and bactericidal activity of cefpiramide and seven antipseudomonal agents against Pseudomonas aeruginosa.
Diagnostic microbiology and infectious disease 1986;5(1):17-23.
1986: D S Davenport; Robert Michael Massanari; Michael A Pfaller; M J Bale; S A Streed; Walter J Hierholzer
Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci.
The Journal of infectious diseases 1986;153(2):332-9.
1986: Michael A Pfaller; M J Bale; K R Schulte; FP Koontz
Comparison of the Quantum II Bacterial Identification System and the AutoMicrobic System for the identification of gram-negative bacilli.
Journal of clinical microbiology 1986;23(1):1-5.
1985: Michael A Pfaller
Automated instrument approaches to clinical microbiology.
Diagnostic microbiology and infectious disease 1985;3(6 Suppl):15S-23S.
1985: Michael A Pfaller; F P Koontz
Laboratory evaluation of leukocyte esterase and nitrite tests for the detection of bacteriuria.
Journal of clinical microbiology 1985;21(5):840-2.
1985: Michael A Pfaller; M Kyriakos; P M Weeks; G S Kobayashi
Disseminated histoplasmosis presenting as an acute tenosynovitis.
Diagnostic microbiology and infectious disease 1985;3(3):251-5.
1985: Michael A Pfaller; F P Koontz
Use of rapid screening tests in processing urine specimens by conventional culture and the AutoMicrobic system.
Journal of clinical microbiology 1985;21(5):783-7.
1985: Michael A Pfaller; G Scharnweber; B Stewart; F P Koontz
Improved urine screening using a combination of leukocyte esterase and the Lumac system.
Diagnostic microbiology and infectious disease 1985;3(3):243-50.
1984: Michael A Pfaller; A C Niles; P R Murray
Evaluation of the Kirby-Bauer disc diffusion test as a screening test for high-level aminoglycoside resistance in enterococci.
American journal of clinical pathology 1984;82(4):458-60.
1984: Michael A Pfaller; D J Krogstad; G G Granich; P R Murray
Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.
Journal of clinical microbiology 1984;20(3):311-6.
1984: Michael A Pfaller; G G Granich; R Valdes; P R Murray
Comparative study of the ability of four aminoglycoside assay techniques to detect the inactivation of aminoglycosides by beta-lactam antibiotics.
Diagnostic microbiology and infectious disease 1984;2(2):93-100.
1984: Michael A Pfaller; A C Niles; P R Murray
In vitro antibacterial activity of cefpiramide.
Antimicrobial agents and chemotherapy 1984;25(3):368-72.
1983: Michael A Pfaller; C A Baum; A C Niles; P R Murray
Clinical laboratory evaluation of a urine screening device.
Journal of clinical microbiology 1983;18(3):674-9.
1983: Michael A Pfaller; D J Krogstad
Oxygen enhances the antimalarial activity of the imidazoles.
The American journal of tropical medicine and hygiene 1983;32(4):660-5.
1983: Michael A Pfaller; L M Westfall; P R Murray
Value of routine aerobic subculturing of unvented blood culture bottles.
Journal of clinical microbiology 1983;17(4):601-4.
1983: Michael A Pfaller; L M Westfall; A C Niles; A Kinroth; P R Murray
Comparison of tryptic soy broth with tryptic soy broth supplemented with sucrose in the septi-chek blood culture system.
Journal of clinical microbiology 1983;17(2):272-5.
1982: Michael A Pfaller; D J Krogstad; A R Parquette; P Nguyen-Dinh
Plasmodium falciparum: stage-specific lactate production in synchronized cultures.
Experimental parasitology 1982;54(3):391-6.
1982: Michael A Pfaller; J J Segal; D J Krogstad
Activity of ketoconazole and its deacyl derivative against Plasmodium falciparum and Candida isolates.
Antimicrobial agents and chemotherapy 1982;22(5):917-9.
1982: Michael A Pfaller; T K Sibley; L M Westfall; J E Hoppe-Bauer; M A Keating; P R Murray
Clinical laboratory comparison of a slide blood culture system with a conventional broth system.
Journal of clinical microbiology 1982;16(3):525-30.
1982: D J Krogstad; G G Granich; P R Murray; Michael A Pfaller; R Valdes
Heparin interferes with the radioenzymatic and homogeneous enzyme immunoassays for aminoglycosides.
Clinical chemistry 1982;28(7):1517-21.
1982: Coy D Fitch; R Chevli; H S Banyal; G Phillips; Michael A Pfaller; D J Krogstad
Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex.
Antimicrobial agents and chemotherapy 1982;21(5):819-22.
1981: Michael A Pfaller; D J Krogstad
Imidazole and polyene activity against chloroquine-resistant Plasmodium falciparum.
The Journal of infectious diseases 1981;144(4):372-5.
1979: Helene Hill; G J Hill; C L Miller; Michael A Pfaller; K Weiss; M Galin
Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
Cancer research 1979;39(3):934-9.
1974: Michael A Pfaller; J J Marr
Antileishmanial effect of allopurinol.
Antimicrobial agents and chemotherapy 1974;5(5):469-72.